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I. Meta-Analysis: Racial Disparities in Prostate Cancer Survival
Prostate cancer is the second leading cause of cancer-related mortality in men. Previous
studies have drawn inconsistent conclusions on racial differences in prostate cancer
survival. This meta-analysis was conducted to investigate the relationship between race
and survival from prostate cancer. A systematic review of published articles from 1968 to
2007 assessing survival from prostate cancer among African American and White men was
conducted. The search yielded 20 eligible published manuscripts. Analysis of unadjusted
studies showed African American men have an increased risk of all-cause mortality
(Hazard ratio (HR) = 1.47, 95% confidence interval (CI): 1.31, 1.65, P < 0.001). However,
examination of adjusted studies showed no difference (HR = 1.07, 95% CI: 0.94, 1.22, P =
0.308). No statistically significant difference was observed in prostate cancer-specific
survival in both analyses using unadjusted (HR = 1.11, 95% CI: 0.94, 1.31, P = 0.209) and
adjusted studies (HR = 1.15, 95% CI: 0.95, 1.41, P = 0.157). There was evidence of
heterogeneity that was unexplained by factors analyzed in overall survival but explained by
stage in prostate cancer-specific survival. This meta-analysis concludes that there are no
racial differences in the overall and prostate cancer-specific survival between African
American and White men.
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II. Case-Control study: Association between Family History of Cancers and Prostate
Cancer
Family history of prostate cancer is an established risk factor for prostate cancer. However,
the relationship between family history of cancers other than prostate cancer and prostate
cancer risk is inconclusive. This study sought to examine the association between family
history of cancers and prostate cancer. A case-control study was conducted in which cases
and controls were randomly selected from a large urology clinic in Central Virginia. Cases
were 600 histologically confirmed prostate cancer patients who were diagnosed between
January 2000 and December 2005, and controls were 686 patients who visited the clinic
during the same period and diagnosed with urological illnesses other than cancers and
prostate-related problems. Data on family history of cancers, lifestyle and demographic
factors were collected. Unconditional logistic regression analysis was used to estimate the
odds ratios and the corresponding 95% confidence intervals after adjustment for potential
confounding factors. Multiple comparisons adjustments were made using Bonferroni
adjustment. Men with family history of any cancer in first-degree relatives including
parents (OR=2.42, 95% CI: 1.53, 3.84) and parents only (OR=1.90, 95% CI: 1.23, 2.94)
were at increased risk of developing prostate cancer compared to men with no such family
history of cancer. Significant increased risk was also observed with family history of
prostate cancer in first-degree relatives (OR=2.68, 95% CI: 1.53, 4.69) and parents only
(OR=3.26, 95% CI: 1.71, 6.24) compared to men with no family history of prostate cancer.
Even after adjustments for multiple comparisons, the significance persisted both in firstdegree relatives (OR=2.68, 95% CI: 1.16, 6.21) and parents alone (OR=3.26, 95% CI:
ix

1.24, 8.63). No association was found with family history of other cancers including
breast, colon, lung, skin, digestive tract, stomach, liver, pancreas, female cancers,
urogenital, urinary bladder, brain, blood and lymph node and other cancers and risk of
prostate cancer. This study demonstrated an increased prostate cancer risk for men with a
family history of any cancer or prostate cancer in first-degree relatives including parents
and parents alone. Health care providers need to be aware of the potential risk of family
history of cancers on prostate cancer.
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III. Case-Control study: Association between Obesity and Prostate Cancer
Obesity is a major public health problem in the United States. Several studies have
investigated the association between obesity and prostate cancer risk. However the impact
of early-adult obesity on prostate cancer is not well studied. This study proposes to
investigate the relationship between prostate cancer and early-onset obesity and current
obesity. A case-control study was conducted to investigate the relationship between
obesity and prostate cancer in a large urology clinic population in Central Virginia. Cases
included histologically confirmed prostate cancer patients of all stages and grades
diagnosed from January 2000 to December 2005. Controls were patients who were
diagnosed with urological illness other than cancers and prostate-related problems. Selfreported data was collected on anthropometric, lifestyle and demographic factors through a
mail survey. Unconditional logistic regression analysis was conducted to investigate the
association between prostate cancer and early-onset obesity (BMI at age 18) and current
obesity. Odds ratios and corresponding 95% confidence intervals were calculated after
accounting for significant interaction terms and adjusting for potential confounding
variables. This study showed statistically significant association between BMI at age 18
and prostate cancer risk in the multivariate analysis when BMI was evaluated as a
continuous variable. There was a 7% decrease in the odds of prostate cancer risk for every
1 kg/m2 increment in BMI at age 18 (OR=0.93, 95% CI: 0.87, 0.98). Analysis of BMI at
age 18 as a categorical variable also showed reduced risk though statistically nonsignificant. Obese men (OR=0.62, 95% CI: 0.12, 3.08) and overweight men (OR=0.60,
95% CI: 0.35, 1.05) had a non-significant decreased risk of developing prostate cancer
xi

compared to normal weight men at age 18. Examination of current BMI showed a nonstatistically significant decreased risk of prostate cancer when examined as a continuous
variable. However, there was significant interaction between current BMI treated
categorically and age. This study concludes that there is decreased prostate cancer risk
associated with increasing BMI at age 18. Future large prospective studies are needed to
better understand the association between early-onset obesity and risk of prostate cancer
and explore the biological factors associated especially in the early ages. This document
was created in Microsoft Word 2003.
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META-ANALYSIS: RACIAL DISPARITIES IN PROSTATE
CANCER SURVIVAL

INTRODUCTION
Prostate cancer is the most common cancer in men excluding basal and squamous
cell skin cancer. In 2008, approximately 186,320 new cases are estimated to be diagnosed
with prostate cancer in the United States.1 This estimate accounts for 25% of all the
cancers diagnosed in men.1 African American men have the highest incidence rates of
prostate cancer. The risk of prostate cancer in African Americans is 60% higher than
White men.2 Prostate cancer is the second leading cause of cancer-related mortality in
men. In the United States, approximately 28,660 men will die from prostate cancer in
2008 alone; accounting for approximately 10% of all the cancers deaths in men.1 The
mortality rate from prostate cancer is 2.4 times higher in African Americans compared to
White men.3
More than 90% of prostate cancers are diagnosed in the local and regional stages
and the 5-year relative survival for these cancers is 100%.1 However, the 5-year relative
survival for distant prostate cancer is significantly lower (31.9%).1 Although overall
survival rates are high, rates differ by race; the 5-year survival rates are approximately
7% higher for Whites than African Americans at all stages. The 5-year survival rate for
localized cancer is approximately 93% for Whites and 86% for African Americans.4
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Disparity in survival rate is also documented for regional (83% vs. 68%) and metastatic
cancers (29% vs. 22%).4
Although descriptive studies show that African Americans are disproportionately
affected by this disease compared to Whites, it is not clear if the increased mortality is
due to race or factors affecting this population such as access to care, quality of care,
socio-economic status, stage and grade of tumor, treatment and comorbidity. Several
researchers have attempted to clarify this disparity by controlling for some of the above
mentioned confounding factors; however, these studies have produced inconsistent
findings.4-19 Several studies have shown that there is an association between race and
survival from prostate cancer4, 15-19 whereas other studies have not found such an
association.5-14
Although several observational studies have had conflicting findings, to our
knowledge there are only two meta-analyses conducted examining the impact of race on
survival from prostate cancer. Overall survival is defined as death due to any cause and
prostate cancer-specific survival is death from prostate cancer as the underlying cause.
The first meta-analysis, by Bach et al. in 2002, included 17 studies that examined racial
differences in prostate cancer survival between Whites and African Americans who
received the same treatment for similar stages of cancer.20 The study showed that African
Americans had a statistically significant increased risk of mortality due to all causes. But
this statistical significance disappeared after adjusting for other causes of death derived
indirectly from population mortality rates from the National Center for Health Statistics
1997 decennial life tables to account only for cancer-specific mortality. This manuscript
examined similar cohorts of men receiving same treatment and similar stages of disease
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and also used indirect adjustment for other causes of death to account for prostate cancerspecific mortality. These results are not generalizable to men with all stages of the
disease who are receiving different treatments and this problem was addressed in the
recent meta-analysis by Evans et al.21 They derived the estimates for prostate cancerspecific mortality directly instead of applying indirect population adjustments.
Evans et al. evaluated 28 studies exploring all-cause and prostate cancer-specific
mortality as potential outcomes.21 The study showed increased statistically significant
risk for overall survival (Hazard ratio (HR) = 1.35, 95% confidence interval (CI): 1.23,
1.48, P < 0.001) and prostate cancer-specific survival (HR = 1.29, 95% CI: 1.13, 1.47, P
< 0.001) among African Americans compared to Whites when using the studies that did
not adjust for any confounders or adjusted only for age. When studies that adjusted for
age, clinical and other socioeconomic factors were used this statistical significance
disappeared for the overall survival (HR = 1.01, 95% CI: 0.88, 1.16, P = 0.93); however,
prostate cancer-specific survival still showed a marginal increased risk of mortality for
African Americans compared to Whites (HR = 1.13, 95% CI: 1.00, 1.27, P = 0.052).
Although this meta-analysis included all the key articles, there was a major
methodological drawback. The authors have included more than one article from the
same SEER cancer registry data, which represented overlapping time periods and
included the same SEER location (San Francisco Bay region) for prostate cancer-specific
mortality.10, 11, 16, 22 When the meta-analysis was repeated after removing the two SEER
articles namely Du et al10 and Polednak et al,11 the increased risk was not statistically
significant (HR = 1.14, 95% CI: 0.95, 1.36, P = 0.15) (confidence interval and P value
obtained through communication with the author). However the article did not discuss
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this crucial information and reported increased risk among African American men for
prostate cancer-specific mortality.
We conducted a meta-analysis of studies that exclusively address the impact of
race, not just as a primary exposure variable, but also as one of the potential independent
variables, on survival in men for localized and advanced prostate cancer. This metaanalysis mitigates the limitations in the previous meta-analyses.20, 21 Recognizing the
varied nature of the studies in terms of standard errors, sample sizes and adjustments for
potential confounding variables, this study utilized two distinct methodologies to
examine the association.
MATERIALS AND METHODS
Study selection
A Medline/PubMed search of published articles in English from 1968 to 2007 was
performed. We used keywords and MESH terms including terms as “prostate cancer”,
“survival”, “mortality” and “race”. We used three levels of screening to select relevant
publications for this analysis. First, two independent reviewers examined all the
identified abstracts to find relevant publications using the criteria that included race as the
primary exposure variable, or at least one of the covariates, and survival either overall or
prostate cancer-specific survival as the outcome. Second, each relevant publication was
examined thoroughly to determine that the inclusion criteria were fulfilled. Additionally,
the reference section of the selected relevant publications was examined for additional
publications that were missed in the initial search. Third, the selected publications were
reviewed and abstracted. At this stage, publications from the same data sources, place and
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overlapping time periods were identified and made sure that only one publication was
selected.
Inclusion and exclusion criteria
The inclusion criteria for this meta-analysis included original research
manuscripts that: a) were published between 1968 and 2007, b) had race, specifically
Whites and African Americans, as the main exposure variable or covariate, c) had overall
survival or prostate cancer-specific survival as one of the outcome variables, d) provided
estimates from which log hazard ratios and standard errors can be calculated directly or
indirectly. We included articles published in English. Review articles or letters were not
included in this analysis. Manuscripts that either compared blacks to non-blacks or nonwhites to whites were also excluded from the analysis.
When there were several publications from the same data source, such as the
SEER cancer registry data, with overlapping time frames and locations, only one
publication was selected to be included in the analysis. Factors such as the most recent
year of publication, larger sample size, number and types of confounders examined,
longer follow-up period, and inclusion of relevant effect sizes were considered to select
publications. Although the initial search yielded 505 publications, only 20 articles met the
inclusion criteria for this analysis (Figure 1). Detailed descriptions of the selected studies
are available in supplementary data.
Out of the 20 publications, 17 studies provided estimates for overall survival.5-10,
23- 33

Thirteen manuscripts had estimates available to calculate the crude overall survival

hazard ratios and 95% confidence intervals directly (2 studies)23, 24 or indirectly from
Kaplan-Meier survival curves (11 studies).5-7, 8, 10, 28-33 Eight manuscripts had estimates
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available to calculate the adjusted overall survival hazard ratios and 95% confidence
intervals directly.7, 9, 10, 23- 27 Prostate cancer-specific survival was reported in nine
manuscripts.10, 12, 23, 25-27, 31, 34, 35 Six manuscripts had estimates available to calculate the
crude hazard ratios and 95% confidence intervals for prostate cancer-specific survival
directly (2 studies)23, 34 or indirectly from Kaplan-Meier survival curves (4 studies).10, 12,
31, 35

Seven manuscripts had estimates available to calculate the adjusted hazard ratios

and 95% confidence intervals for prostate cancer-specific survival directly.10, 12, 23, 25- 27, 34
Some studies provided both unadjusted and adjusted estimates, while others reported only
the unadjusted or adjusted effect sizes.
Data abstraction
Data abstraction form was developed and two independent reviewers abstracted
relevant information from the selected publications. Information including bibliographic
information (authors, title, journal of publication and date, whether peer reviewed or not),
study setting (study location, type, name and data source), study population
characteristics (age, race, stage and grade of cancer), study design details (sample size,
year of prostate cancer diagnosis, length of follow-up), model characteristics (exposure
variable, outcome variable, other covariates assessed and controlled for confounders) and
study results (hazard ratios and 95% confidence intervals or p values from Cox
proportional hazard regression, Kaplan-Meier survival curves) were abstracted.
Statistical analysis
The selected publications reported different estimates for the association between
race and survival, including hazard ratios and 95% confidence intervals or P values from
Cox proportional hazard regression or Kaplan-Meier survival curves. We used log hazard
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ratios and standard errors to determine the summary hazard ratios and 95% confidence
intervals. The method described by Parmar et al was used to derive the log hazard ratios
and standard errors directly for the manuscripts providing hazard ratios and 95%
confidence intervals or P values.36 The log hazard ratios and standard errors were
determined indirectly for the crude analysis using Parmar et al.36 and Microsoft Excel
spreadsheets provided by Tierney et al.37 from Kaplan-Meier survival curves.
Depending on the results of the tests for heterogeneity including Q statistic and I2
statistic a decision was made whether to use fixed effects or Dersimonian-Laird random
effects model. As the tests for heterogeneity was significant in all the analysis, random
effects model results are reported.
To account for the differences among the studies in terms of standard errors,
sample size and adjustment for confounders, weighted analysis was considered.
Weighting the studies with respect to standard errors is straight forward. In addition to
this, weighting the studies according to their other characteristics that are considered
important in public health studies was also considered. We believe studies that adjust for
these variables provide valid information about the racial differences than those that do
not and therefore, the studies with adjusted analysis received a higher weight. For this
purpose an objective quality scoring method was utilized to assign scores to each study.
Previous publications have provided mixed opinions on whether quality scoring
should be used as a weighting variable. Some manuscripts comment that quality scoring
adds subjective bias, may lack validity and results may not represent quality. 38-41 Other
studies claim that quality scoring can be done, but recommend not using the scores as
weights but rather use the summary score as a covariate to conduct subgroup and
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sensitivity analysis. 40, 42, 43 As suggested in the literature, this study utilized standard
error as weighting variable and investigated if the analysis using summary score as
weighting variable also holds true with this analysis. These two distinct methods were
considered to maximize the validity of this meta-analysis.
In order to preserve objectivity of the scoring, only the factors that are important
predictors of prostate cancer and those that do not pose any scoring ambiguity, such as
age of the patient, stage of the disease, grade of the tumor, treatment, comorbidity,
socioeconomic status, pre biopsy PSA levels and sample size of the study were
considered. Moreover, two independent researchers scored these studies so that reliability
could be established. Based on the quality scores, weights proportional to the scores were
calculated. That is, a study with higher score received a higher weight. Then the analysis
was performed in two ways: first, with weights obtained from standard errors alone, then
by using summary weights that are averages of the weights based on the standard errors
and the weights based on the quality scores.
Funnel plots were used to examine publication bias. Sensitivity analysis was
performed to determine robustness of the meta-analysis. To examine the effects of small
and outlier studies we removed one study at a time and repeated the analysis with the
remaining studies. Further subgroup and meta-regression analysis were done on selected
covariates to identify potential explanations for heterogeneity among studies. All analysis
was done using STATA Statistical software version 10.1 (StataCorp, College Station,
TX). All p-values were two-sided and values less than 0.05 were considered significant.
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RESULTS
(A) Overall survival
Unadjusted and adjusted summary estimates using standard error as weights.
Pooled estimate from the 13 studies with unadjusted estimates showed a statistically
significant increased risk of mortality among African American men compared to White
men (HR = 1.47, 95% CI: 1.31, 1.65, P < 0.001). However, no statistically significant
difference was observed in the analysis using the adjusted hazard ratios from the eight
studies that adjusted for age, clinical and other demographic variables (HR = 1.07, 95%
CI: 0.94, 1.22, P = 0.308). Figure 2 shows that there was evidence of heterogeneity
among the studies in the adjusted analysis (Q = 36.45, df 7, P < 0.001).
Adjusted summary estimates using summary score as weights. Utilizing summary
score as weights evenly distributed the weights among the studies compared to using
standard error as weights. Conversely, the summary estimates from the eight adjusted
studies remained the same (HR = 1.06, 95% CI: 0.90, 1.25, P = 0.463) compared to the
pooled estimates obtained using standard error as weights.
Table 1 compares the summary estimates derived from the standard error and
summary score methods for the unadjusted, adjusted and overall analysis. The findings
from the two methods were fairly similar and comparable.
Publication bias. Figure 3 shows equal dispersion of studies. Both the unadjusted
and adjusted models showed no evidence of publication bias in the funnel plots.
Sensitivity analysis. Small studies and potential outliers were identified using
standard errors and funnel plots. These studies were removed one at a time and the
summary estimates were evaluated each time. In the unadjusted analysis, removal of the
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following small studies and outliers provided the following estimates: Zagars et al (HR =
1.44, 95% CI: 1.29, 1.61, P < 0.001)29, Powell et al (HR = 1.52, 95% CI: 1.35, 1.71, P <
0.001)6 , and Hussain et al (HR = 1.38, 95% CI: 1.27, 1.49, P < 0.001).33 Eliminating all
three manuscripts at the same time yielded similar results as the overall unadjusted
analysis (HR = 1.35, 95% CI: 1.29, 1.41, P < 0.001).
In the adjusted analysis, removing the following studies resulted in the following
estimates: Halabi et al (HR = 1.12, 95% CI: 0.99, 1.28, P = 0.069)25 , Freeman et al (HR
= 1.02, 95% CI: 0.91, 1.14, P = 0.745)27 , and Optenberg et al (HR = 1.10, 95% CI: 0.97,
1.25, P = 0.155).7 Excluding all the three manuscripts at the same time produced similar
results as the overall adjusted analysis (HR = 1.08, 95% CI: 1.00, 1.17, P = 0.065).
Subgroup and Meta-regression analysis. Subgroup and meta-regression analysis
were conducted across several covariates to explain the heterogeneity among the studies
(Table 2 and 3). The analysis showed that the heterogeneity observed among the studies
examining overall survival cannot be explained by any of the covariates including stage,
recruitment year or study type.
(B) Prostate cancer-specific survival
Unadjusted and adjusted summary estimates using standard error as weights.
Evaluation of the six studies with unadjusted estimates showed no statistically significant
excess risk of prostate cancer-specific mortality among African American men compared
to White men (HR = 1.11, 95% CI: 0.94, 1.31, P = 0.209). Similarly, analysis of the
seven studies with the adjusted estimates also showed no increased risk among African
American men compared to White men (HR = 1.15, 95% CI: 0.95, 1.41, P = 0.157).
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Further examination of these studies showed evidence of heterogeneity among the studies
in the adjusted analysis (Q = 22.46, df 6, P = 0.001) (Figure 4).
Adjusted summary estimates using calculated summary score as weights. A
modest difference in weights occurred when quality scores were added to the weights
obtained from standard errors, compared to the weights from standard error alone. The
pooled estimates from the seven adjusted studies did not change (HR = 1.17, 95% CI:
0.96, 1.43, P = 0.113) compared to the estimates obtained using standard error as
weights. Summary estimates derived from the standard error and summary score methods
yielded consistent findings for the unadjusted, adjusted and overall analysis (Table 4).
Publication bias. Funnel plots showed equal dispersion of studies and no evidence
of publication bias in both unadjusted and adjusted models (Figure 5).
Sensitivity analysis. Exclusion of Fowler et al (HR = 1.17, 95% CI: 1.02, 1.33, P
= 0.022)12 , Kim et al (HR = 1.05, 95% CI: 0.90, 1.23, P = 0.520)31 , Roach et al (HR =
1.07, 95% CI: 0.91, 1.26, P = 0.435)23 and all manuscripts at the same time (HR = 1.05,
95% CI: 0.97, 1.15, P = 0.229) yielded similar findings as the overall unadjusted
analysis.
In the adjusted analysis, removing studies including Halabi et al (HR = 1.22, 95%
CI: 1.09, 1.35, P < 0.001)25, Freeman et al (HR = 1.08, 95% CI: 0.90, 1.31, P = 0.395)27 ,
and both manuscripts at the same time (HR = 1.18, 95% CI: 1.06, 1.32, P = 0.003)
resulted in statistically significant estimates compared to the summary estimates obtained
in the pooled adjusted analysis.
Subgroup and Meta-regression analysis. The heterogeneity among the studies
examining the association between race and prostate cancer-specific survival can be
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explained by stage of the disease including local/regional (HR = 1.17, 95% CI: 1.04,
1.32, P = 0.009), metastatic (HR = 0.76, 95% CI: 0.63, 0.92, p=0.005), recruitment
period in 1987 or earlier (HR = 1.19, 95% CI: 1.02, 1.38, P = 0.026) and retrospective
cohort study types (HR = 1.22, 95% CI: 1.07, 1.39, P = 0.004) in the subgroup analysis
and by metastatic stage in the meta-regression analysis (Table 5 and 6).
DISCUSSION
This study found no statistically significant increased risk of mortality due to all
causes and prostate cancer-specific causes in African American men compared to White
men. These results were consistent with the observations made by Bach et al who showed
no increased risk in African Americans compared to Whites for prostate cancer-specific
survival.20 While the overall survival results of this study was consistent to the findings
observed by Evans et al., inconsistency between the two studies was observed in the
prostate cancer-specific mortality.21 Evans et al. showed increased risk in prostate cancerspecific survival whereas this study observed no increased risk.21
The major reason for this discrepancy in the prostate cancer-specific survival
analysis between these studies may be due to the differences in manuscript selection. This
meta-analysis only included one manuscript from the SEER cohort that spanned across all
11 SEER sites, that is most recent, had a large sample size and was comprehensive.10
However, Evans et al21 utilized four studies from the SEER cohorts that not only had
overlapping time periods but also included the San Francisco Bay region (Table 7).10, 11,
16, 22

When Evans et al. conducted sensitivity analysis and excluded Du et al10 and

Polednak et al11 from the prostate cancer-specific survival analysis, they also observed no
increased risk (HR = 1.14, 95% CI: 0.95, 1.36, P = 0.15) consistent with our analysis.
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This manuscript excluded some studies due to the inclusion/exclusion criteria for
reasons including estimates not available.44-46 Additionally, this study included only one
publication from University of Texas MD Anderson Cancer Center47 and SEER
cohorts.11, 16, 18, 22
Unlike other studies, this meta-analysis has several strengths. It addresses and
accounts for serious methodological flaws observed in other studies. The study excluded
more than one manuscript from the SEER registry data with overlapping time periods and
only included one publication from the SEER registry data. Additionally, this study
evaluated all published manuscripts from 1968 to 2007 and excluded manuscripts not
meeting the inclusion criteria compared to the earlier meta-analyses.
The limitations of this study include that it only includes published manuscripts
from 1968 to 2007. This excludes unpublished studies and usually unpublished studies
are more likely to show negative results. Therefore this study may be overestimating the
summary hazard ratios due to exclusion of those manuscripts. However, the tests showed
no evidence of publication bias. In the adjusted analysis there was evidence for
heterogeneity that was accounted for by performing random effects modeling, subgroup
analysis and meta-regression analysis. However, the potential still exists for a lack of
homogeneity among all the studies used to produce the summary hazard ratios.
In conclusion, there are no differences between African American and Whites in
survival from prostate cancer. Future studies are needed to study the racial disparity in
prostate cancer survival.
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Table 1. Summary Estimates Comparing Standard Error and Summary Score Methods for
Overall Survival

Unadjusted
Adjusted
Overall
*All P values are two-sided

Standard error
1.47 (1.31, 1.65), P <0.001
1.07 (0.94, 1.22), P = 0.308
1.29 (1.13, 1.47), P <0.001

Summary score
1.52 (1.31, 1.78), P <0.001
1.06 (0.90, 1.25), P = 0.463
1.30 (1.12, 1.52), P = 0.001

Table 2. Subgroup Analysis for Overall Survival
Subgroups

Summary
hazard ratios

95% confidence
intervals

P value

No. of
studies

Local/regional
Metastatic
All stages

1.02
0.88
1.39

0.98, 1.06
0.60, 1.30
0.90, 2.13

0.424
0.511
0.135

3
3
2

Yes
No

1.06
1.11

0.91, 1.22
0.88, 1.40

0.470
0.370

4
4

1.03

0.77, 1.40

0.830

3

1.09

0.93, 1.29

0.285

5

Stage

Recruitment
period in PSA
era or earlier

Study type
Randomized
control trial
Retrospective
cohort study
*All P values are two-sided
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Table 3. Meta-regression Analysis for Overall Survival
Subgroups

Summary
hazard ratios

95% confidence
intervals

P value

Local/regional
Metastatic
All stages

1.00
0.69
1.37

0.43, 1.12
0.87, 2.16

0.131
0.172

Yes
No

0.83
1.00

0.57, 1.20
-

0.317
-

1.27

0.81, 1.98

0.305

1.00

-

-

Stage

Recruitment
period in PSA
era or earlier

Study type
Randomized
control trial
Retrospective
cohort study
*All P values are two-sided
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Table 4. Summary Estimates Comparing Standard Error and Summary Score Methods for
Prostate Cancer-Specific Survival

Unadjusted
Adjusted
Overall
*All P values are two-sided

Standard error
1.11 (0.94, 1.31), P = 0.209
1.15 (0.95, 1.41), P = 0.157
1.12 (0.97, 1.30), P = 0.128

Summary score
1.14 (0.91, 1.44), P = 0.262
1.17 (0.96, 1.43), P = 0.113
1.16 (0.98, 1.38), P = 0.092

Table 5. Subgroup Analysis for Prostate Cancer-Specific Survival
Subgroups

Summary
hazard ratios

95% confidence
intervals

P value

No. of
studies

Local/regional
Metastatic
All stages

1.17
0.76
1.47

1.04, 1.32
0.63, 0.92
0.99, 2.17

0.009
0.005
0.055

4
1
2

Yes
No

1.19
1.14

1.02, 1.38
0.75, 1.72

0.026
0.540

4
3

0.97

0.59, 1.59

0.899

2

1.22

1.07, 1.39

0.004

5

Stage

Recruitment
period in PSA
era or earlier

Study type
Randomized
control trial
Retrospective
cohort study
*All P values are two-sided
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Table 6. Meta-regression Analysis for Prostate Cancer-Specific Survival
Subgroups

Summary
hazard ratios

95% confidence
intervals

P value

Local/regional
Metastatic
All stages

1.00
0.53
1.28

0.35, 0.81
0.96, 1.71

0.003
0.098

Yes
No

0.89
1.00

0.69, 1.13
-

0.330
-

1.18

0.84, 1.67

0.342

1.00

-

-

Stage

Recruitment
period in PSA
era or earlier

Study type
Randomized
control trial
Retrospective
cohort study
*All P values are two-sided
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Table 7. Listing of Studies using the SEER Registry Data
No.

Author and
year
Robbins et al
(2000)16

Recruitment
period
1973-1993

2

Polednak et
al (2003)11

1988-1997

3

OakleyGirvan et al
(2003)22

1987-1991

4

Du et al
(2006)10

1992-1999

1
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Source
SEER - San
Francisco Bay
region
9 SEER sites
including Atlanta,
Connecticut,
Detroit, Hawaii,
Iowa, New
Mexico, San
Francisco/Oakland,
Seattle-Puget
Sound and Utah
SEER – Hawaii,
Los Angeles, San
Francisco and
Vancouver
11 SEER sites
including San
Francisco/Oakland,
Detroit, Atlanta,
Seattle, Los
Angeles county,
San Jose-Monterey
area, Connecticut,
Iowa, New
Mexico, Utah and
Hawaii

Population
characteristics
All prostate
cancer cases
Advanced
prostate
cancer cases

All prostate
cancer cases

Local/regional
stage prostate
cancer cases

Figure 1. Flowchart of study selection criteria

Medline search
“prostate cancer”,
“survival”, “mortality” and
“race”
Identified 505
publications
First level abstract search
Race as the main exposure
variable or at least one of
the covariates and overall
survival or cause-specific
survival as one of the
outcome variables
Identified 115
abstracts
Second level publication
search
Reviewed each publication
to determine if it met the
inclusion criteria, relevant
estimates available and
further reference search

Identified 52
publications

Third level search
One publication per study or
dataset or location with
relevant data

Identified 20
publications
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Figure 2. Forest plot of studies with adjusted estimates for overall survival

Hazard
StudyName

Year

Ratio (95% CI)

Roach

2003

1.17 (0.96, 1.43)

Thompson

2001

1.23 (1.04, 1.46)

Halabi

2006

0.77 (0.65, 0.92)

Du

2006

1.01 (0.97, 1.06)

Tewari

2006

1.02 (0.88, 1.19)

Freeman

2004

1.75 (1.33, 2.30)

Optenberg

1995

0.64 (0.40, 1.04)

Dayal

1985

1.13 (0.96, 1.33)
1.07 (0.94, 1.22)

Overall

NOTE: Weights are from random effects analysis
.397

1
AA have lower mortality

2.52
AA have higher mortality

Figure 3. Funnel plots of studies with unadjusted and adjusted estimates for overall
survival
Begg's funnel plot with pseudo 95% confidence limits

Begg's funnel plot with pseudo 95% confidence limits
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Figure 4. Forest plot of studies with adjusted estimates for prostate cancer-specific
survival

Hazard
StudyName

Year

Ratio (95% CI)

Roach

2003

1.26 (0.96, 1.66)

Halabi

2006

0.76 (0.63, 0.92)

Du

2006

1.17 (0.99, 1.38)

Tewari

2006

1.11 (0.87, 1.41)

Freeman

2004

1.84 (1.22, 2.78)

Fowler

2000

1.23 (0.90, 1.68)

Iselin

1998

1.22 (0.67, 2.21)
1.15 (0.95, 1.40)

Overall

NOTE: Weights are from random effects analysis
.359

1
AA have lower mortality

2.78
AA have higher mortality

Figure 5. Funnel plots of studies with unadjusted and adjusted estimates for prostate
cancer-specific survival
Begg's funnel plot with pseudo 95% confidence limits
Begg's funnel plot with pseudo 95% confidence limits
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CASE-CONTROL STUDY: ASSOCIATION BETWEEN FAMILY
HISTORY OF CANCERS AND PROSTATE CANCER

INTRODUCTION
Prostate cancer is the most common cancer among men in the United States. It
accounts for about 25% of all the cancers diagnosed in men.1 Family history of prostate
cancer is a well established risk factor for prostate cancer risk in men. Several
prospective 2, 3, 4, 5 and retrospective6, 7, 8, 9, 10, 11, 12, 13 studies have reported a two to fourfold increased risk of prostate cancer in men with a positive family history of prostate
cancer especially in a first-degree relative.
To date, three meta-analyses have confirmed the association between family
history of prostate cancer and risk of prostate cancer in men. They consistently concluded
that there was an increased risk of prostate cancer in men with affected first-degree
family members; and the risk was greater for men with affected brother than affected
father, increases with decreasing age of the patient and family members and increasing
number of affected individuals in the family.14, 15, 16
However there are only limited studies exploring the association between family
history of other forms of cancers other than prostate cancer and risk of developing
prostate cancer. Some studies have implicated family history of breast cancer as a risk
factor for prostate cancer 6, 17, 18, 19, 20, 21, 22, 23, 24, 25 whereas others have not.2, 26, 27, 28, 29, 30
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Similarly, a few studies have shown an association between family history of colorectal
cancer, 4, 22 ovarian cancer,31 kidney cancer,25, 31, 32, 33 stomach cancer,25, 34 esophageal
cancer,28, 31 , bladder cancer,31 , brain cancer,35 , leukemia,35 , central nervous system,36
and prostate cancer risk in men. However, a number of studies have not found such an
association with certain cancers.2, 6, 20, 26, 27, 28, 31, 35, 37
The major problem with existing corpus of literature was the inability of
investigators to control for potential confounders. It was evident that some of these
studies were only able to control for the effect of age and other studies were not able
control for any of the potential confounding factors due to inadequate sample size. Small
sample size and neglecting the impact of other demographic and lifestyle factors have
had potential impact on the association. It is also important to note that some of these
studies utilized cancer registry data to calculate the observed and expected incidence rates
and examined the association between family history of different cancers and prostate
cancer risk, which may not be accurate. The data in the cancer registries is obtained from
hospital and medical records and only limited to information and accuracy available in
those datasets. Additionally, it is important to note that most of the studies exploring
family history of cancers and prostate cancer were conducted in countries other than the
US. The few studies conducted in the US predominantly focused on Caucasian
population.
In conclusion, the methodological limitations of the current body of literature are
evident and require further investigation. This study proposes to investigate the
association between family history of cancers and risk of prostate cancer in a
heterogeneous population in Central Virginia.
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MATERIALS AND METHODS
Study design
The study sample included 3,710 patients from a large, multi-site private urology
practice located in Central Virginia. Cases were a random sample of 1,237 patients with
histologically confirmed diagnosis of prostate cancer. This included prostate cancers of
all stages and grades diagnosed from January 2000 to December 2005. Controls were a
random sample of 2,473 patients who visited the clinic during the same time as the cases
and were diagnosed with urological illnesses other than cancers and prostate-related
problems including prostatitis and chronic prostate hypertrophy. Patients with prostaterelated problems or any urological cancer were excluded to reduce misclassification bias.
Furthermore, chronic prostatitis and benign prostate hypertrophy were not included
because of the potential link with excess risk of prostate cancer.38, 39, 40 Additionally, this
study excluded patients diagnosed before January 2000 and after December 2005, who
were non-English speaking and unable to complete the questionnaire due to mental or
cognitive problems.
Data collection
A mail survey was conducted to collect data on family history of cancers, life
style behaviors and demographic information. Data included family history of cancers,
age, race, education, employment, income, marital history, height, weight, behavioral risk
factors such as diet history, sunlight exposure, smoking habits, alcohol use, physical
activity, STD history and history of vasectomy. The survey included validated questions
from the BRFSS,41, 42, 43 NHIS,44 NHANES,45 Family history survey, 46 and Nurses’
health study47 surveys. Information on family history of cancers was obtained using the
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family history table from Quillin et al.46 The question asked to complete a family history
table and indicate if there were family members diagnosed with cancers, their
relationship with the patient, the type of cancer, age at diagnosis, the side of the family
(maternal or paternal) and if they died from the cancer.
The survey was conducted after the questionnaire was pre-tested and approved by
the institutional review board. The mail survey utilized the method suggested by
Dillman.48 First, a brief pre-notice postcard was mailed in first class mail to the selected
3,510 participants. Four weeks after the pre-notice postcard, the questionnaire was mailed
to 3,490 participants after excluding those who did not want to be contacted (n=4) and
deceased (n=16). Five days after the questionnaire was mailed, a thank-you letter was
sent to 3,271 participants after removing those who did not want to be contacted (n=2),
deceased (n=2) and wrong addresses without forwarding addresses (n=215). Two weeks
after the thank-you letter, a replacement questionnaire was mailed to 2,219 nonresponders as a reminder to complete the survey after excluding deceased (n=57), those
who did not want to participate (n=37), valid surveys returned (n=862), wrong addresses
(n=68) and other reasons (n=28). This mailing methodology yielded an overall 37%
response rate; a total sample size of 1,286 participants (600 cases and 686 controls).
Definitions of variables
Patient status, having prostate cancer (case) and no prostate cancer (control)
served as the outcome variable. The main exposure variable family history of cancers was
defined as self-reported history of cancers including prostate, breast, colon, lung, skin,
digestive tract, stomach, liver, pancreas, female cancers, urogenital, urinary bladder,
brain, blood and lymph node and other cancers among first-degree relatives including
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parents, siblings or offspring and also parents and siblings separately. Other covariates
including BMI (<25 kg/m2, 25-29.99 kg/m2, ≥30 kg/m2), physical activity (0 days per
week, 1-2 days per week, ≥3 days per week), alcohol consumption (0 drinks per day, 1-2
drinks per day, ≥3 drinks per day), smoking (non-smoker, former smoker, current
smoker), diet including fruits and vegetables intake (<2 servings per day, 2-4 servings per
day, >4 servings per day), milk consumption (never, at least once per week, ≥1 time per
day), vitamin intake (yes, no), history of vasectomy (yes, no) and STD (yes, no), age
(≤60, 61-70, >70), race (White, African American, Hispanic, Other), marital status
(married, divorced, never married), education (less than grade 12, grade 12 or GED, some
college, college graduate) and income (less than $25,000, $25,000 to less than $50,000,
$50,000 to less than $75,000, $75,000 to less than $100,000, $100,000 or more) were
collected.
Statistical analysis
A descriptive analysis was done to examine the distribution of the study
participants and assess the comparability of cases and controls. Chi square test and pvalues were calculated to examine the association between categorical variables.
Univariate analysis was conducted using the main exposure variable and other
covariates. The association between family history of any cancer and cancer at each
location including prostate, breast, colon, lung, skin, digestive tract, stomach, liver,
pancreas, female cancers, urogenital, urinary bladder, brain, blood and lymph node and
other cancers in first-degree relatives, parents and siblings alone and risk of developing
prostate cancer in men were estimated using unconditional logistic regression. Firstdegree relatives were defined as parents, siblings or off-springs. Odds ratios and
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corresponding 95% confidence intervals were determined in the multivariate analysis
after accounting for the potential confounding variables. Multiple comparisons
adjustments were made using Bonferroni adjustment. All the analysis was conducted in
SAS version 9.1 and all the tests were two-sided. Comparison between responders and
non-responders would be appropriate; however, information on non-responders was not
available.
RESULTS
The study sample included 600 cases (47%) and 686 controls (53%). Cases were
more likely to be older than controls but less likely to be college educated and have high
income (Table 1). Cases and controls were similar in marital status and race distribution.
About 52.4% of the cases were over 70 years old compared to 12.4% in the controls.
Cases had about 45% college educated and 22% with some college education compared
to 46% and 26% in controls respectively. More cases had less than high school education
(14% compared to 6% in controls). One-fourth of the cases made over $100,000 per years
compared to 35% among controls. Over 40% of the cases made less than $50,000 per
year compared to 25% of the controls. Both cases and controls had over 80% Whites,
about 10% African Americans, over 80% married and about 15% divorced.
In the crude analysis, compared to men with no family history of cancers, those
who have family history of any cancer in first-degree relatives were 1.8 times more likely
to develop prostate cancer (Table 2). An increased risk was also observed with history of
cancers in siblings. Compared to men with no family history of cancers, those who have
family history of any cancer in siblings were 2.6 times respectively more likely to
develop prostate cancer. Significant increased risk was also shown with family history of
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prostate cancer in first-degree relatives, only parents and siblings compared to men with
no family history of prostate cancer. Compared to men with no family history of lung
cancer, men with a family history of lung cancer in siblings were at increased prostate
cancer risk (OR=4.56, 95% CI: 1.95, 10.68). There was a significant protective effect
observed with family history of skin cancer in first-degree relatives (OR=0.55, 95% CI:
0.32, 0.94) and just parents (OR=0.47, 95% CI: 0.25, 0.91) compared to men with no
family history of skin cancer.
Adjusted analysis confirmed that men with family history of any cancer in firstdegree relatives were 2.42 times more likely to develop prostate cancer (OR=2.42, 95%
CI: 1.53, 3.84) compared to men with no family history of cancers (Table 2). Men with
family history of any cancer in parents alone were 1.90 times more likely to develop
prostate cancer (OR=1.90, 95% CI: 1.23, 2.94) compared to men with no family history
of cancers. Significant increased risk was observed with family history of prostate cancer
in first-degree relatives (OR=2.68, 95% CI: 1.53, 4.69) and only parents (OR=3.26, 95%
CI: 1.71, 6.24) compared to men with no family history of prostate cancer. Even after
adjustments for multiple comparisons, there was a statistically significant increased risk
among men with family history of prostate cancer in first-degree relatives (OR=2.68,
95% CI: 1.16, 6.21) and parents alone (OR=3.26, 95% CI: 1.24, 8.63) compared to men
with no family history of prostate cancer. Men who have a family history of brain cancer
in first-degree relatives were 9.09 times more likely to develop prostate cancer (OR=9.09,
95% CI: 1.48, 55.96) compared to men with no family history of brain cancer. This
association lost its statistical significance when adjustments were made for multiple
comparisons (OR=9.09, 95% CI: 0.60, 138.64) (Table 2).
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DISCUSSION
This study showed that there was increased prostate cancer risk associated with
family history of any cancer in first-degree relatives. Specifically men with family history
of any cancer only in parents were two times more likely to develop prostate cancer. This
is similar to the observation in the population-based case-control study conducted at
Shanghai, China where a 1.79 times increased prostate cancer risk was reported with any
type of cancer in first-degree relatives (OR=1.79, 95% CI: 1.21, 2.63) and 2.21 times
increased risk was observed with any type of cancer in only parents compared to no
family history of any cancer (OR=2.21, 95% CI: 1.31, 3.73).28 Negri et al. also reported
that family history of cancer at all sites (OR=1.5, 95% CI: 1.3, 1.8) and family history of
cancer at all sites excluding prostate cancer (OR=1.3, 95% CI: 1.1, 1.6) in first-degree
relatives was associated with an increased risk of prostate cancer.31 On the other hand, a
case-control study conducted in Italy showed 1.6 times increased risk with family history
of cancer in all sites in first-degree relatives (OR=1.6, 95% CI: 1.2, 2.3) but reported no
statistically significant risk with family history of cancer in all sites excluding prostate
cancer in first-degree relatives (OR=1.2, 95% CI: 0.8, 1.7).35
Consistent with the past literature 2, 6, 17, 19, 20, 26, 27, 29, 30, 31, 35 this study showed a
two fold increased risk of prostate cancer among men with family history of prostate
cancer in first-degree relatives and three fold increased risk for those with family history
of prostate cancer in only parents. This significance persisted even after adjusting for
multiple comparisons.
This study concluded that men who have a family history of brain cancer in firstdegree relatives were 9.09 times more likely to develop prostate cancer. This finding is
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similar to the conclusions made by the case-control study conducted in Italy in 2007
among men 60 years or less.35 They found that men with family history of brain cancer
in first-degree relatives were 3.7 times more likely to develop prostate cancer (OR=3.7,
95% CI: 1.2, 11.7). The current study found a stronger association and this could be
explained by the fact that Gallus et al. study had 8 cases and 6 controls with family
history of brain cancer compared to 13 cases and 5 controls with family history of brain
cancer in the present study. This result has to be interpreted with caution due to small cell
sizes, wide confidence intervals and multiple comparisons. Small changes in the cell sizes
can drastically change the estimates. It is important to note that the statistical significance
was lost after adjustment for multiple comparisons. So the association that we observed
may be due to chance. But studies have shown that Li-fraumeni syndrome occurring in
young patients with an aggregation of cancers including brain tumor, leukemia,
adrenocortical carcinoma, breast cancer and sarcoma could occasionally be accompanied
by prostate cancer and this is attributed to germline mutation in p53.20 Future large
prospective studies with larger cell sizes and adequate control for potential confounders
are needed to confirm is this association is due to chance or if there is a genetic
component and co-clustering with other cancers.
There was a non-statistically significant decreased risk associated with skin
cancer in the unadjusted analysis both among first-degree relatives (OR=0.55, 95% CI:
0.32, 0.94) and just parents (OR=0.47, 95% CI: 0.25, 0.91) that disappeared after
adjusting for potential confounders. This finding has never been shown or explored in
any other studies before. Many studies exclude skin cancers which may be due to the
reason that skin cancer is underreported as reporting is not mandatory except for
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melanoma and skin cancer is the most common and curable cancer. This result could be
due to chance but should be explored further in future studies or could be due to shared
genetic factors.
The current study found non-significant increased risk with family history of
cancers including breast, colon, lung, digestive tract, pancreas, female cancers,
urogenital, bladder and blood and lymph node. Linkage studies have shown co-clustering
between prostate cancer, breast, ovarian and colon cancer due to BRCA 1 and 2 genes in
the chromosome 17q.49, 50 But our study did not find an association between family
history of breast, ovarian and colon cancer and prostate cancer. This could be due to
extensive control for potential confounders.
This study found non-significant decreased risk with stomach and liver cancers
both in first-degree relatives and parents alone. In contrast, past studies have shown nonsignificant increased risk associated with stomach and liver cancer both in first-degree
relatives and parents alone.28, 31 This difference noted may be due to extensive control for
confounders in the present study but there are no apparent biological explanations
available for this finding.
Knowledge of family history of cancers is very important. It helps distinguish
between the hereditary and sporadic cancers that have some key differences. A review
article by Bratt et al. in 2002 examined the differences in clinical characteristics between
hereditary and sporadic prostate cancer.55 They found that one major difference between
the hereditary and sporadic cancer is that hereditary prostate cancer is diagnosed at least 6
or 7 years earlier than sporadic cancer.55 But hereditary and sporadic prostate cancers do
not have any differences in tumor grade or pathological stage at diagnosis.56, 57, 58, 59

39

Studies have shown mixed findings with differences in outcomes between hereditary and
sporadic cancers 57, 59, 60, 61 As a result of early diagnosis, more men with hereditary
prostate cancer tend to die due to the disease.55 This difference calls for early screening
in men with family history of cancer specifically prostate cancer and other cancers. A
recent US randomized control trial, Prostate, Lung, Colorectal and Ovarian cancer
screening study 62 reported that routine PSA screening has no effect in reducing the rate
of death from prostate cancer. However, a European randomized study on prostate cancer
screening 63 concluded that there was a decrease in death rate due to prostate cancer by
20% but there was an increased risk of overdiagnosis. Therefore PSA screening may not
be mandatory and necessary in sporadic prostate cancers. However, in the case of
hereditary prostate cancer, early PSA screening may be necessary so that the cancer can
be diagnosed and treated at early stages and grades. But it is necessary to conduct
randomized control trials to confirm that early diagnosis and treatment of hereditary
prostate cancers improves survival and quality of life. To determine if a patient has a
hereditary or sporadic prostate cancer, knowledge of family history of cancers is very
crucial.
Potential strengths of this study include good response rate to mail surveys,
extensive collection of data and control of known and potential confounders, thorough
exploration of family history of several cancers on prostate cancer risk and adjusting for
multiple comparisons in the analysis. This study collected and controlled for extensive
list of known and potential confounders and controlled for them in the data analysis. Past
studies had controlled either only for age or had a partial control for confounders. This
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could have partly played a role in past studies showing more statistically significant
results. 2, 19, 20, 28, 31, 35, 37
Limitations include that there may have been a problem of misclassification of the
family history as it is based on self-reported data. No additional validation of the selfreported information was conducted. However, past studies have shown that self-reported
family history data can be accurate. Two studies from Sweden and US have shown that
self-reported family history of prostate cancer in prostate cancer cases have an accuracy
of 92% and 86% respectively. King et al. also found accuracy of self-reported family
history with other cancers- 95% for breast cancer, 92% for colon cancer, 100% for
bladder and kidney cancer and 82% for all sites.51, 52, 53, 54 Considering the design of this
study, it is possible that the cases over reported and the controls under reported the
exposure resulting in overestimation of the association. The crude estimate was
calculated using the proportions of family history of prostate cancer in cases and controls
from a meta-analysis by Bruner et al. This yielded estimate similar to the estimate
obtained in the current study.15
Another inherent problem with case-control study is recall bias as cases may
recall family history of cancers different than the controls. This could overestimate our
results. This study used clinic controls and they may be different from the general
population controls. It is possible that the cases and controls may share common risk
factors and this may underestimate the association. Since the cases were selected from
this clinic, it is a preferred population to select the controls from the same clinic to be
comparable. But patients with any urological cancer and prostate-related problem were
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excluded and controls were selected from a variety of diagnosis to reduce
misclassification of controls.
This study was done in a private urology clinic and majority of the cases may
more have been referred to this clinic. This makes the cases different from the control
population and may overestimate the association. However, differential referral patterns
between cases and controls were not expected since the study participants were urology
patients. The mail survey obtained an overall 37% response but a 53% response rate
among cases and 29% among controls. If the non-responders are systematically different
from the responders, this can overestimate or underestimate the association. It is possible
that cases or those with family history of cancers may be more willing to respond than the
controls or those without the risk factor; resulting in underestimation of the association.
However, information on non-responders was not available in this study to assess
comparability of non-responders with responders.
The current study showed that there is an increased risk of prostate cancer for men
with a family history of any cancer and prostate cancer in first-degree relatives and
parents alone. But the association between family history of other cancers and prostate
cancer risk was not statistically significant. Future studies should be conducted to explore
the association between family history of other cancers and prostate cancer risk in a large
prospective follow-up study accounting for known and potential confounders.
Additionally, future studies should examine the genetic and shared environmental
influences associated with prostate cancer risk. This is important as the hereditary and
sporadic cancers behave differently in terms of mortality. Knowledge of family history of
cancers is very important to differentiate hereditary and sporadic cancers. Health care
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practitioners need to be educated about the importance of family history of cancers so
that this information can be routinely collected.

43

LIST OF REFERENCES

44

List of References

1. American Cancer Society. Cancer Facts & Figures 2008. Atlanta: American Cancer
Society; 2008.
2. Ahn J, Moslehi R, Weinstein SJ, Snyder K, Virtamo J, Albanes D. Family history of
prostate cancer and prostate cancer risk in the alpha-tocopherol, beta-carotene cancer
prevention (ATBC) study. Int J Cancer. 2008;123:1154-1159.
3. Giovannucci E, Liu Y, Platz EA, Stampfer MJ, Willett WC. Risk factors for prostate
cancer incidence and progression in the health professionals follow-up study. Int J
Cancer. 2007;121:1571-1578.
4. Damber L, Gronberg H, Damber JE. Familial prostate cancer and possible associated
malignancies: Nation-wide register cohort study in sweden. Int J Cancer. 1998;78:293297.
5. Schuurman AG, Zeegers MP, Goldbohm RA, van den Brandt PA. A case-cohort study
on prostate cancer risk in relation to family history of prostate cancer. Epidemiology.
1999;10:192-195.
6. Suzuki T, Matsuo K, Wakai K, et al. Effect of familial history and smoking on
common cancer risks in japan. Cancer. 2007;109:2116-2123.
7. Staples MP, Giles GG, English DR, et al. Risk of prostate cancer associated with a
family history in an era of rapid increase in prostate cancer diagnosis (australia). Cancer
Causes Control. 2003;14:161-166.

45

8. Whittemore AS, Wu AH, Kolonel LN, et al. Family history and prostate cancer risk in
black, white, and asian men in the united states and canada. Am J Epidemiol.
1995;141:732-740.
9. Steinberg GD, Carter BS, Beaty TH, Childs B, Walsh PC. Family history and the risk
of prostate cancer. Prostate. 1990;17:337-347.
10. Ghadirian P, Howe GR, Hislop TG, Maisonneuve P. Family history of prostate
cancer: A multi-center case-control study in canada. Int J Cancer. 1997;70:679-681.
11. Lesko SM, Rosenberg L, Shapiro S. Family history and prostate cancer risk. Am J
Epidemiol. 1996;144:1041-1047.
12. Andersson SO, Baron J, Bergstrom R, Lindgren C, Wolk A, Adami HO. Lifestyle
factors and prostate cancer risk: A case-control study in sweden. Cancer Epidemiol
Biomarkers Prev. 1996;5:509-513.
13. Keetch DW, Rice JP, Suarez BK, Catalona WJ. Familial aspects of prostate cancer: A
case control study. J Urol. 1995;154:2100-2102.
14. Zeegers MP, Jellema A, Ostrer H. Empiric risk of prostate carcinoma for relatives of
patients with prostate carcinoma: A meta-analysis. Cancer. 2003;97:1894-1903.
15. Bruner DW, Moore D, Parlanti A, Dorgan J, Engstrom P. Relative risk of prostate
cancer for men with affected relatives: Systematic review and meta-analysis. Int J
Cancer. 2003;107:797-803.
16. Johns LE, Houlston RS. A systematic review and meta-analysis of familial prostate
cancer risk. BJU Int. 2003;91:789-794.
17. Chen YC, Page JH, Chen R, Giovannucci E. Family history of prostate and breast
cancer and the risk of prostate cancer in the PSA era. Prostate. 2008;68:1582-1591.

46

18. Rodriguez C, Calle EE, Tatham LM, et al. Family history of breast cancer as a
predictor for fatal prostate cancer. Epidemiology. 1998;9:525-529.
19. Beebe-Dimmer JL, Drake EA, Dunn RL, Bock CH, Montie JE, Cooney KA.
Association between family history of prostate and breast cancer among african-american
men with prostate cancer. Urology. 2006;68:1072-1076.
20. Hayes RB, Liff JM, Pottern LM, et al. Prostate cancer risk in U.S. blacks and whites
with a family history of cancer. Int J Cancer. 1995;60:361-364.
21. Tulinius H, Egilsson V, Olafsdottir GH, Sigvaldason H. Risk of prostate, ovarian, and
endometrial cancer among relatives of women with breast cancer. BMJ. 1992;305:855857.
22. Goldgar DE, Easton DF, Cannon-Albright LA, Skolnick MH. Systematic populationbased assessment of cancer risk in first-degree relatives of cancer probands. J Natl
Cancer Inst. 1994;86:1600-1608.
23. Bennett KE, Howell A, Evans DG, Birch JM. A follow-up study of breast and other
cancers in families of an unselected series of breast cancer patients. Br J Cancer.
2002;86:718-722.
24. Valeri A, Fournier G, Morin V, et al. Early onset and familial predisposition to
prostate cancer significantly enhance the probability for breast cancer in first degree
relatives. Int J Cancer. 2000;86:883-887.
25. Gronberg H, Bergh A, Damber JE, Emanuelsson M. Cancer risk in families with
hereditary prostate carcinoma. Cancer. 2000;89:1315-1321.
26. Cerhan JR, Parker AS, Putnam SD, et al. Family history and prostate cancer risk in a
population-based cohort of iowa men. Cancer Epidemiol Biomarkers Prev. 1999;8:53-60.

47

27. McCahy PJ, Harris CA, Neal DE. Breast and prostate cancer in the relatives of men
with prostate cancer. Br J Urol. 1996;78:552-556.
28. Bai Y, Gao YT, Deng J, Sesterhenn IA, Fraumeni JF, Hsing AW. Risk of prostate
cancer and family history of cancer: A population-based study in china. Prostate Cancer
Prostatic Dis. 2005;8:60-65.
29. Kalish LA, McDougal WS, McKinlay JB. Family history and the risk of prostate
cancer. Urology. 2000;56:803-806.
30. Karakiewicz PI, Foulkes W, Tanguay S, Elhilali MM, Aprikian AG. Familial prostate
and breast cancer in men treated with prostatectomy for prostate cancer: A population
based case-control study. J Urol. 2003;169:240-244.
31. Negri E, Pelucchi C, Talamini R, et al. Family history of cancer and the risk of
prostate cancer and benign prostatic hyperplasia. Int J Cancer. 2005;114:648-652.
32. Hemminki K, Vaittinen P. Effect of paternal and maternal cancer on cancer in the
offspring: A population-based study. Cancer Epidemiol Biomarkers Prev. 1997;6:993997.
33. Eldon BJ, Jonsson E, Tomasson J, Tryggvadottir L, Tulinius H. Familial risk of
prostate cancer in iceland. BJU Int. 2003;92:915-919.
34. Matikaine MP, Pukkala E, Schleutker J, et al. Relatives of prostate cancer patients
have an increased risk of prostate and stomach cancers: A population-based, cancer
registry study in finland. Cancer Causes Control. 2001;12:223-230.
35. Gallus S, Foschi R, Talamini R, et al. Risk factors for prostate cancer in men aged
less than 60 years: A case-control study from italy. Urology. 2007;70:1121-1126.

48

36. Isaacs SD, Kiemeney LA, Baffoe-Bonnie A, Beaty TH, Walsh PC. Risk of cancer in
relatives of prostate cancer probands. J Natl Cancer Inst. 1995;87:991-996.
37. Randi G, Pelucchi C, Negri E, et al. Family history of urogenital cancers in patients
with bladder, renal cell and prostate cancers. Int J Cancer. 2007;121:2748-2752.
38. Dennis LK, Dawson DV. Meta-analysis of measures of sexual activity and prostate
cancer. Epidemiology. 2002;13:72-79.
39. Kearse WS,Jr, Seay TM, Thompson IM. The long-term risk of development of
prostate cancer in patients with benign prostatic hyperplasia: Correlation with stage A1
disease. J Urol. 1993;150:1746-1748.
40. Chokkalingam AP, Nyren O, Johansson JE, et al. Prostate carcinoma risk subsequent
to diagnosis of benign prostatic hyperplasia: A population-based cohort study in sweden.
Cancer. 2003;98:1727-1734.
41. Centers for Disease Control and Prevention (CDC). Behavioral Risk Factor
Surveillance System Survey Questionnaire. Atlanta, Georgia: U.S. Department of Health
and Human Services, Centers for Disease Control and Prevention, 2006.
42. Centers for Disease Control and Prevention (CDC). Behavioral Risk Factor
Surveillance System Survey Questionnaire. Atlanta, Georgia: U.S. Department of Health
and Human Services, Centers for Disease Control and Prevention, 2005.
43. Centers for Disease Control and Prevention (CDC). Behavioral Risk Factor
Surveillance System Survey Questionnaire. Atlanta, Georgia: U.S. Department of Health
and Human Services, Centers for Disease Control and Prevention, 2000.

49

44. National Center for Health Statistics (NCHS). National Health Interview Survey.
Hyattsville, MD: U.S. Department of Health and Human Services, Centers for Disease
Control and Prevention, 2005.
45. National Center for Health Statistics (NCHS). National Health and Nutrition
Examination Survey. Hyattsville, MD: U.S. Department of Health and Human Services,
Centers for Disease Control and Prevention, 2003-2004.
46. Quillin JM, Ramakrishnan V, Borzelleca J, Bodurtha J, Bowen D, Baer Wilson D.
Paternal relatives and family history of breast cancer. Am J Prev Med. 2006;31:265-268.
47. The Nurses’ Health Study. Available at
http://www.channing.harvard.edu/nhs/questionnaires/index.shtml. Accessed 8/29, 2007.
48. Dillman DA. Mail and Internet Surveys-the Tailored Design Method. John Wiley and
Sons, Inc.; 2000.
49. Arason A, Barkardottir RB, Egilsson V. Linkage analysis of chromosome 17q
markers and breast-ovarian cancer in icelandic families, and possible relationship to
prostatic cancer. Am J Hum Genet. 1993;52:711-717.
50. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE. Risks of cancer in BRCA1mutation carriers. breast cancer linkage consortium. Lancet. 1994;343:692-695.
51. Aitken J, Bain C, Ward M, Siskind V, MacLennan R. How accurate is self-reported
family history of colorectal cancer? Am J Epidemiol. 1995;141:863-871.
52. Kerber RA, Slattery ML. Comparison of self-reported and database-linked family
history of cancer data in a case-control study. Am J Epidemiol. 1997;146:244-248.

50

53. Bratt O, Kristoffersson U, Lundgren R, Olsson H. Familial and hereditary prostate
cancer in southern sweden. A population-based case-control study. Eur J Cancer.
1999;35:272-277.
54. King TM, Tong L, Pack RJ, Spencer C, Amos CI. Accuracy of family history of
cancer as reported by men with prostate cancer. Urology. 2002;59:546-550.
55. Bratt O. Hereditary prostate cancer: Clinical aspects. J Urol. 2002;168:906-913.
56. Bastacky SI, Wojno KJ, Walsh PC, Carmichael MJ, Epstein JI. Pathological features
of hereditary prostate cancer. J Urol. 1995;153:987-992.
57. Bratt O, Damber JE, Emanuelsson M, Gronberg H. Hereditary prostate cancer:
Clinical characteristics and survival. J Urol. 2002;167:2423-2426.
58. Keetch DW, Humphrey PA, Smith DS, Stahl D, Catalona WJ. Clinical and
pathological features of hereditary prostate cancer. J Urol. 1996;155:1841-1843.
59. Valeri A, Azzouzi R, Drelon E, et al. Early-onset hereditary prostate cancer is not
associated with specific clinical and biological features. Prostate. 2000;45:66-71.
60. Kupelian PA, Klein EA, Witte JS, Kupelian VA, Suh JH. Familial prostate cancer: A
different disease? J Urol. 1997;158:2197-2201.
61. Gronberg H, Isaacs SD, Smith JR, et al. Characteristics of prostate cancer in families
potentially linked to the hereditary prostate cancer 1 (HPC1) locus. JAMA.
1997;278:1251-1255.
62. Andriole GL, Grubb RL,3rd, Buys SS, et al. Mortality results from a randomized
prostate-cancer screening trial. N Engl J Med. 2009.
63. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality
in a randomized european study. N Engl J Med. 2009.

51

Table 1: Distribution of the study characteristics
Cases (%)

Controls (%)

≤60
61-70
>70

70 (13.2)
183 (34.4)
279 (52.4)

375 (59.7)
175 (27.9)
78 (12.4)

White
African American
Hispanic
Other

474 (81.0)
63 (10.8)
40 (6.8)
8 (1.4)

563 (83.0)
63 (9.3)
33 (4.9)
19 (2.8)

Married
Divorced
Never Married

498 (83.7)
90 (15.1)
7 (1.2)

557 (82.0)
95 (14.0)
27 (4.0)

<Grade 12
Grade 12 or GED
Some college
College graduate
Household income
< $25,000
$25,000 to < $50,000
$50,000 to < $75,000
$75,000 to < $100,000
≥ $100,000
BMI
≤24.99
25-29.99
≥30
Moderate activity (in days per
week)
0
1-2
≥3
Alcohol (drinks per day)
0
1-2
≥3
Smoking
Current smoker
Former smoker
Non-smoker
Fruits and Vegetables (servings per
day)
<2
2-4
>4

80 (13.8)
113 (19.5)
126 (21.8)
260 (44.9)

41 (6.2)
147 (22.2)
172 (26.0)
301 (45.5)

69 (14.0)
132 (26.8)
95 (19.3)
74 (15.0)
123 (25.0)

55 (9.0)
107 (17.5)
134 (21.9)
100 (16.4)
215 (35.2)

178 (30.5)
281 (48.2)
124 (21.3)

145 (21.6)
302 (44.9)
226 (33.6)

82 (15.1)
86 (15.8)
377 (69.2)

106 (16.6)
124 (19.4)
408 (64.0)

203 (39.1)
285 (54.9)
31 (6.0)

174 (28.8)
391 (64.6)
40 (6.6)

43 (7.2)
62 (10.3)
495 (82.5)

87 (12.7)
46 (6.7)
553 (80.6)

145 (25.3)
264 (46.1)
164 (28.6)

208 (31.1)
305 (45.6)
156 (23.3)

Age (Years)

Race

Marital status

Education

52

Cases (%)

Controls (%)

52 (9.0)
328 (57.0)
195 (33.9)

60 (9.2)
397 (61.2)
192 (29.6)

390 (66.0)
201 (34.0)

418 (61.8)
258 (38.2)

155 (27.4)
411 (72.6)

193 (29.0)
473 (71.0)

50 (8.6)
530 (91.4)

84 (12.4)
592 (87.6)

Milk (servings)
Never
At least 1 time per week
≥1 time per day
Vitamin intake
Yes
No
Vasectomy
Yes
No
STD
Yes
No

53

Liver

Stomach

Digestive tract

Skin

Lung

Colon

Breast

Prostate

Any cancer

Yes
No

Yes
No

Yes
No

Yes
No

Yes
No

Yes
No

Yes
No

Yes
No

Yes
No

Family history of cancers

1.06 (0.53, 2.14)
1.00

1.15 (0.46, 2.86)
1.00

0.63 (0.30, 1.31)
1.00

0.55 (0.32, 0.94)
1.00

1.25 (0.87, 1.81)
1.00

1.34 (0.88, 2.04)
1.00

1.11 (0.77, 1.58)
1.00

2.77 (1.99, 3.86)
1.00

1.83 (1.40, 2.38)
1.00

0.70 (0.24, 1.99)
1.00

0.44 (0.09, 2.11)
1.00

1.18 (0.41, 3.42)
1.00

0.86 (0.37, 1.98)
1.00

1.41 (0.79, 2.53)
1.00

1.12 (0.55, 2.28)
1.00

1.09 (0.58, 2.05)
1.00

2.68 (1.53, 4.69)**
1.00

2.42 (1.53, 3.84)
1.00

First-degree relatives
Crude OR
Adjusted OR*
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0.67 (0.28, 1.60)
1.00

1.28 (0.41, 3.99)
1.00

0.42 (0.15, 1.16)
1.00

0.47 (0.25, 0.91)
1.00

0.83 (0.55, 1.25)
1.00

1.22 (0.74, 2.00)
1.00

0.84 (0.55, 1.27)
1.00

1.88 (1.28, 2.75)
1.00

1.09 (0.85, 1.40)
1.00

Crude OR

0.45 (0.13, 1.54)
1.00

0.64 (0.09, 4.48)
1.00

0.55 (0.10, 3.06)
1.00

0.73 (0.27, 1.96)
1.00

1.22 (0.64, 2.30)
1.00

1.17 (0.52, 2.63)
1.00

1.00 (0.48, 2.07)
1.00

3.26 (1.71, 6.24)****
1.00

1.90 (1.23, 2.94)
1.00

Parents
Adjusted OR*

Table 2: Association of family history of cancers and risk of developing prostate cancer

3.01 (0.77, 11.69)
1.00

0.96 (0.21, 4.29)
1.00

1.28 (0.45, 3.67)
1.00

0.63 (0.24, 1.70)
1.00

4.56 (1.95, 10.68)
1.00

1.96 (0.98, 3.89)
1.00

1.85 (0.98, 3.48)
1.00

4.85 (2.74, 8.60)
1.00

2.64 (1.95, 3.58)
1.00

3.92 (0.25, 62.62)
1.00

0.24 (0.02, 3.51)
1.00

2.65 (0.59, 11.87)
1.00

1.19 (0.28, 5.04)
1.00

1.91 (0.48, 7.60)
1.00

1.84 (0.53, 6.36)
1.00

1.10 (0.35, 3.48)
1.00

2.13 (0.88, 5.19)
1.00

1.55 (0.94, 2.56)
1.00

Siblings
Crude OR
Adjusted OR*

1.81 (0.47, 7.00)
1.00

1.10 (0.37, 3.25)
1.00

1.14 (0.31, 4.24)
1.00
2.07 (0.56, 7.65)
1.00
9.09 (1.48, 55.96)***
1.00
1.80 (0.68, 4.72)
1.00
0.60 (0.22, 1.63)
1.00

1.28 (0.59, 2.80)
1.00

1.37 (0.68, 2.74)
1.00

1.28 (0.57, 2.88)
1.00
2.06 (0.99, 4.30)
1.00
3.38 (1.20, 9.56)
1.00
1.41 (0.79, 2.52)
1.00
0.54 (0.28, 1.05)
1.00

First-degree relatives
Crude OR
Adjusted OR*

0.28 (0.11, 0.75)
1.00

1.11 (0.52, 2.35)
1.00

1.80 (0.57, 5.70)
1.00

1.68 (0.73, 3.86)
1.00

1.54 (0.47, 5.07)
1.00

1.02 (0.40, 2.61)
1.00

1.14 (0.44, 2.97)
1.00

Crude OR

0.42 (0.10, 1.78)
1.00

2.68 (0.82, 8.71)
1.00

6.79 (0.92, 50.10)
1.00

2.00 (0.41, 9.90)
1.00

2.59 (0.38, 17.44)
1.00

1.17 (0.25, 5.49)
1.00

1.13 (0.23, 5.49)
1.00

Parents
Adjusted OR*

1.12 (0.40, 3.11)
1.00

2.22 (0.87, 5.68)
1.00

4.52 (0.93, 21.85)
1.00

0.73 (0.21, 2.50)
1.00

1.71 (0.59, 4.97)
1.00

1.60 (0.43, 5.99)
1.00

0.65 (0.15, 2.86)
1.00

0.86 (0.19, 3.84)
1.00

2.14 (0.22, 21.05)
1.00

0.21 (0.02, 2.67)
1.00

1.03 (0.23, 4.67)
1.00

4.74 (0.36, 62.92)
1.00

Siblings
Crude OR
Adjusted OR*
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*Adjusted for BMI, alcohol intake, physical activity, smoking, diet, history of vasectomy and STD, age, race, marital history, education and income
** Bonferroni corrected estimate 2.68 (1.16, 6.21)
*** Bonferroni corrected estimate 9.09 (0.60, 138.64)
**** Bonferroni corrected estimate 3.26 (1.24, 8.63)

Yes
No
Female cancers (uterus,
ovary, cervix, vagina)
Yes
No
Urogenital (kidney,
rectum, ureter, testis)
Yes
No
Urinary bladder
Yes
No
Brain
Yes
No
Blood and lymph node
Yes
No
Other
Yes
No

Pancreas

Family history of cancers

CASE-CONTROL STUDY: ASSOCIATION BETWEEN OBESITY
AND PROSTATE CANCER

INTRODUCTION
Obesity is a major public health problem in the United States and affects over
30% of the adult population. The prevalence of obesity in adults has continued to
increase over the past several decades. The recent 2003-04 data published by the National
Health and Nutrition Examination Survey (NHANES), which measured height and
weight from 4,431 adults, showed that 32.2% of the adult population in the US was
obese.1
Disease conditions including diabetes, hypertension, high cholesterol, asthma,
arthritis and poor health status are associated with obesity.2 Furthermore, prospective
studies have shown that there is increased risk of death due to cardiovascular disease and
several cancers including prostate cancer in men who are obese.3, 4, 5 Prostate cancer is the
most common malignant neoplasm in men. In 2008 alone, approximately 186,320 new
cases were estimated to be diagnosed in the United States.6 Several studies have explored
the association between obesity and risk of developing prostate cancer in men. These
studies have shown mixed findings between higher BMI and prostate cancer risk.
The most recent prospective study using over 280,000 men who participated in
the NIH-AARP diet and health study showed significant decreased risk with localized
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prostate cancer for men with BMI ≥40 kg/m2 compared to men in lower BMI category
<25 kg/m2 (RR=0.67, 95% CI: 0.50, 0.89) and extraprostatic disease with BMI 35-39.9
kg/m2 compared to men in lower BMI category <25 kg/m2 (RR=0.68, 95% CI: 0.49,
0.94).7 Similarly, the prospective study using the cohort of 50,000 men from the Health
Professionals follow-up study found that men with high BMI of ≥ 30kg/m2 compared to
men in normal BMI category 23-24.9 kg/m2 had lower risk of developing prostate cancer
among those who were less than 60 years old (RR=0.52, 95% CI: 0.33, 0.83) or had a
family history of prostate cancer (RR=0.74, 95% CI: 0.45, 1.19).8
A meta-analysis looking at 31 cohort studies and 25 case-control studies from
1966 to 2004 found that obesity was weakly associated with prostate cancer (RR=1.05
per 5 kg/m2 increment, 95% CI: 1.01, 1.08). There was increased risk observed with
advanced disease (RR=1.12 per 5 kg/m2 increment, 95% CI: 1.01, 1.23) and decreased
risk with localized disease (RR=0.96 per 5 kg/m2 increment, 95% CI: 0.89, 1.03).9 A
large Swedish retrospective cohort study conducted on 135,000 construction workers
with an average of 18 years follow-up also showed a non-significant positive association
between prostate cancer risk and weight, height, BMI >26.2 kg/m2 (RR=1.13, 95% CI:
0.99, 1.29) compared to BMI <22.1 kg/m2 and lean body mass. The association was
stronger for prostate cancer mortality than prostate cancer incidence.10 Several other
studies have shown that obesity increases the risk of developing prostate cancer.11, 12, 13, 14,
15

In contrast, numerous studies have shown that there is no association between
obesity and risk of prostate cancer.16, 17, 18, 19, 20, 21, 22, 23, 24, 25 Furthermore, a report from
the Baltimore longitudinal study of aging revealed that greater waist to hip ratio was
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associated with an increased but not statistically significant risk for prostate cancer both
in age-adjusted and multivariate analysis adjusted for age, smoking and fasting insulin.26
The Netherlands cohort study that followed over 58,000 men for 6.3 years also found no
association between BMI and development of prostate cancer.27 The Health Professionals
study in the US also assessed the relationship between anthropometric measurements and
prostate cancer risk on 47,781 men. The study showed that adult BMI, and hip and waist
circumferences were not associated with risk of total or advanced prostate cancer.28
Recent studies have show that higher BMI is associated with increased risk of
advanced prostate cancer and has a protective effect on localized early prostate cancer. A
prospective study from the Cancer Prevention Study II cohort found that BMI ≥ 35kg/m2
was inversely associated with risk of non-metastatic low-grade prostate cancer (RR=0.84,
95% CI: 0.66, 1.06) compared to BMI <25kg/m2. It further found that BMI 30-<35kg/m2
compared to BMI <25kg/m2 was positively associated with risk of non-metastatic highgrade prostate cancer (RR=1.22, 95% CI: 0.96, 1.55) and metastatic and fatal prostate
cancer (RR=1.54, 95% CI: 1.06, 2.23).29 Another study from the Prostate cancer
prevention trial found that obese men with BMI ≥ 30kg/m2 compared to BMI <25kg/m2
had an 18% decreased risk of low grade prostate cancer (RR=0.82, 95% CI: 0.69, 0.98)
and 29% increased risk of high grade prostate cancer (RR=1.29, 95% CI: 1.01, 1.67).30
Majority of these studies have looked at obesity in late adult life either before
cancer diagnosis or study onset. It is important to examine the effects of obesity in early
childhood and adulthood on prostate cancer risk to determine the true association before
the cancer process has begun. Studying obesity in late adult life during study onset or
before cancer diagnosis may not be a true indicator as the cancerous conversion may have
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already started. To our knowledge, there is only one recent systematic review and metaanalysis that studied the association between early-adult obesity and prostate cancer risk.
Robinson et al. analyzed nine cohort and seven case-control studies that explored the
association between early-adult BMI and prostate cancer risk. They showed that there
was non-significant increased prostate cancer risk associated with five-unit increase in
early-adult BMI (RR=1.06, 95% CI: 0.99, 1.14). Additionally, this study showed limited
evidence of protective effect between early-adult obesity and advanced prostate cancer
but not with localized cancer.31
Compared to the wealth of literature examining obesity before cancer diagnosis or
at the time of study entry and prostate cancer risk, the studies addressing early-onset
obesity and prostate cancer risk are limited. Only a few studies as addressed in the metaanalysis by Robinson et al. have looked at early-onset obesity and prostate cancer risk.31
Some of these studies looking at early-onset obesity showed increased risk of prostate
cancer 13, 16, 18, 22, 23, 27, 32, 33 whereas others showed decreased risk.7, 28, 34, 35 The scant
literature in this area has also presented several methodological problems. Most of these
studies have examined BMI only as a categorical variable with inconsistent definitions
and cut-off points. The inconsistency in the definition of obesity has made comparability
of these studies very difficult. Although most studies have used BMI to determine
obesity, studies have categorized obesity into different ranges disregarding the standard
and internationally accepted World Health Organization (WHO) categories. Another
limitation of these studies is also the poor and inconsistent control of confounders with
some studies only controlling for age. There is no adequate control for individual level
demographic, behavioral and clinical factors. Therefore the current study investigated the
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relationship between early-onset obesity, current obesity and prostate cancer risk
controlling for known and postulated confounding factors, utilizing the widely accepted
WHO definitions for categorizing BMI. This study also evaluated BMI both as
categorical and continuous variable.
MATERIALS AND METHODS
Study design
This study used data from a case-control study conducted in Central Virginia
between September and October 2008. The study was designed to examine the influence
of obesity, lifestyle behaviors and demographic factors on prostate cancer.
Study setting and population
Potential study participants (N=3,710) were recruited from a private urology
practice that consists of nine clinics serving Central Virginia. Cases (N=1,237) were
randomly selected from histologically confirmed prostate cancer patients of all stages and
grades diagnosed from January 2000 to December 2005. Controls included a random
sample of 2,473 urologic patients other than cancers and prostate-related problems who
were diagnosed during the same time period. This study excluded patients diagnosed
before January 2000 and after December 2005, non-English speaking and those with
mental and cognitive problems who cannot complete the questionnaire.
Data collection
Before the beginning of the study, data collection instrument was pre-tested and
necessary adjustments were made. To enhance the response rate, this study used the
Dillman mail survey methodology.36 The survey procedure included a series of mailings
including a pre-notice postcard, questionnaire, thank-you letter and a replacement
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questionnaire. Initially a pre-notice postcard was mailed to 3,510 potential study
participants informing them the intent of the study. The questionnaire accompanied by a
cover letter and a return envelope was mailed following the pre-notice postcard. A thankyou letter was then sent to 3,271 participants after removing the deceased, wrong
addresses and those who did not want to be contacted. Two weeks after the thank-you
letter, 2,219 participants were sent with a final reminder and replacement questionnaire.
Overall a 37% response rate was obtained and 1,286 (600 cases and 686 controls) valid
questionnaires were collected. Adequate information was not available on the nonresponders and therefore comparison between responders and non-responders was not
done.
Measurement of covariates
Validated questions from the BRFSS,37, 38, 39 NHIS,40 NHANES,41 Family
history survey,42 and Nurses’ health study43 surveys were adopted. Data on current
height, weight and weight at age 18 were collected. Lifestyle factors such as diet history,
sunlight exposure, smoking habits, alcohol use, physical activity, STD history and history
of vasectomy and demographic information including age, race, education, employment,
income, marital status were also collected. Relevant questions to collect all the necessary
information on lifestyle and demographic factors were not available in one standardized
questionnaire. Therefore appropriate questions were selected from several validated
questionnaires, combined and used in the mail survey.
The main outcome variable for this study was patient status (cases and controls).
Cases were prostate cancer patients regardless of the stage and severity of the disease.
Controls were patients who visited the clinic for urological problems other than cancers
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and prostate problems. The main exposure variable obesity was depicted by BMI, defined
as weight (in kilograms) divided by square of the height (in meters). BMI was
categorized in accordance to the World Health Organization classification as, normal
(BMI less than 25kg/m2), overweight (BMI 25-29.9 kg/m2) and obese (BMI >=30
kg/m2).44 Covariates such as, physical activity (0 days per week, 1-2 days per week, ≥3
days per week), alcohol consumption (0 drinks per day, 1-2 drinks per day, ≥3 drinks per
day), smoking (non-smoker, former smoker, current smoker), diet including fruits and
vegetables intake (<2 servings per day, 2-4 servings per day, >4 servings per day), milk
consumption (never, at least once per week, ≥1 time per day), vitamin intake (yes, no),
history of vasectomy (yes, no) and STD (yes, no), age (≤60, 61-70, >70), race (White,
African American, Hispanic, Other), marital status (married, divorced, never married),
education (less than grade 12, grade 12 or GED, some college, college graduate) and
income (less than $25,000, $25,000 to less than $50,000, $50,000 to less than $75,000,
$75,000 to less than $100,000, $100,000 or more) were examined.
Statistical analysis
The association between BMI and risk of developing prostate cancer were
estimated using unconditional logistic regression. Univariate analysis was done using the
main exposure variable and other covariates. Four unconditional multiple logistic
regression models were built to examine the associations between prostate cancer and
BMI. BMI at age 18 and current BMI was examined both as categorical and continuous
variable. Interaction effects were assessed using the likelihood ratio test and then
potential confounders were assessed using the 10% change in estimate rule. Odds ratios
and corresponding 95% confidence intervals were determined after accounting for
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potential interactions and adjusting for the potential confounding variables. Data analysis
was performed in SAS version 9.1 and all the statistical tests were two-sided.
RESULTS
Distribution of the study characteristics
The demographic and characteristics of the population are described in Table 1.
Majority of the men were white (82.1%), married (82.8%), college graduate (45.2%) or
have completed some college (24.0%). About half the participants earn $75,000 or more
per year (46.4%). About 81% of the men were normal weight at age 18 whereas 46% of
them were overweight and 28% obese at present. Cases were more likely to be older than
controls but less likely to college educated and have high income. They are both similar
in race and marital status distributions.
BMI at age 18
The crude analysis showed that being overweight at age 18 had a significant
protective effect on prostate cancer risk. Overweight men at age 18 had a 39% decreased
risk of prostate cancer (OR=0.61, 95% CI: 0.44, 0.84) compared to normal weight men.
On the other hand, obese men had a 43% decreased risk compared to normal weight men;
however, this association was not statistically significant (OR=0.57, 95% CI: 0.24, 1.35).
Test for trend showed a statistically significant trend associated with increasing BMI and
decreasing prostate cancer risk (P = 0.002).
A statistically significant decreased risk of prostate cancer was also observed
when BMI was analyzed as a continuous variable. Per unit increase in BMI, there was
6% reduced odds of prostate cancer risk (OR=0.94, 95% CI: 0.91, 0.97). Additionally, a
statistically significant association was observed between family history of prostate
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cancer and risk of developing prostate cancer in men (OR=2.76, 95% CI: 2.05, 3.72)
compared to men with no family history of prostate cancer. Increasing age had a
significant increased prostate cancer risk (Table 2).
When the effect of potential confounders was controlled, BMI at age 18 remained
significant. There was a 7% decrease in the odds of developing prostate cancer for every
unit increase in BMI (OR=0.93, 95% CI: 0.87, 0.98) (Table 2). However, the association
lost its statistical significance when BMI at age 18 was analyzed as a categorical variable.
Although not statistically significant the direction of association remained the same;
showing that overweight men at age 18 (OR=0.60, 95% CI: 0.35, 1.05) and obese men at
age 18 (OR=0.62, 95% CI: 0.12, 3.08) had a non-significant decreased risk of developing
prostate cancer compared to normal weight men.
Family history of prostate cancer remained statistically significant in the adjusted
analysis both when BMI at age 18 was treated as categorical and continuous variable.
Compared to men with no family history, men with a family history of prostate cancer
were 2.85 times more likely to develop prostate cancer (OR=2.85, 95% CI: 1.77, 4.58).
Similarly, when BMI at age 18 was analyzed as continuous variable, there was increased
prostate cancer risk associated with family history of prostate cancer compared to no
history of prostate cancer (OR=2.99, 95% CI: 1.91, 4.69). There was a statistically
significant association between age and risk of developing prostate cancer. Men who
were between 61-70 years old were 8.52 times more likely to develop prostate cancer
(OR=8.52, 95% CI: 5.23, 13.88) compared to men 60 years old or younger. Similarly,
men 70 years and over had an increased risk of prostate cancer (OR=23.82, 95% CI:
13.67, 41.51) compared to men 60 years or younger (Table 2).
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Current BMI
There was a statistically significant association between currently obese men and
prostate cancer in the unadjusted analysis. Currently obese men were 0.45 times less
likely to develop prostate cancer compared to normal weight men (OR=0.45, 95% CI:
0.33, 0.61) whereas currently overweight men were 0.76 times less likely to develop
prostate cancer though not statistically significant (OR=0.76, 95% CI: 0.58, 1.00)
compared to normal weight men. There was an evident trend of decreasing risk of
prostate cancer with increasing BMI (P<.0001). There was statistically significant
decreased risk in prostate cancer for a unit increase in BMI when evaluated as a
continuous variable (OR=0.94, 95% CI: 0.92, 0.96) (Table 2).
Adjusted analysis showed that there was a non-significant decreased prostate
cancer risk for a unit increase in BMI (OR=0.97, 95% CI: 0.92, 1.02) when BMI was
analyzed as a continuous variable (Table 2). When BMI was examined as a categorical
variable, there was a significant interaction between current BMI and age. Among men
aged 60 years or less, overweight men had an increased risk of developing prostate
cancer compared to normal weight men (OR=1.01, 95% CI: 0.59, 1.74) and obese men
had a decreased risk (OR=0.73, 95% CI: 0.38, 1.40) compared to normal weight men,
though not statistically significant. In the 61-70 years old age category, both overweight
men (OR=0.73, 95% CI: 0.34, 1.57) and obese men (OR=0.44, 95% CI: 0.18, 1.10) were
less likely to develop prostate cancer compared to normal weight men. This association
was also not statistically significant. Similar relationship was observed in men over 70
years with overweight (OR=0.71, 95% CI: 0.27, 1.87) and obese men (OR=0.74, 95% CI:
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0.22, 2.56) having decreased prostate cancer risk compared to normal weight men (Table
3 and Figure 1).
Increased prostate cancer risk was evident with having a family history of prostate
cancer compared to no family history and increasing age both when BMI was evaluated
and categorical and continuous variable. Additionally, there was a two fold increased risk
of prostate cancer in African American men compared to White men when BMI was
analyzed as a continuous variable (OR=2.39, 95% CI: 1.15, 4.94) (Table 2).
DISCUSSION
This study showed that there was statistically significant decreased prostate
cancer risk associated with increasing BMI at age 18 when evaluated as a continuous
variable. To our knowledge, there were only two other studies examining BMI as a
continuous variable to define early-onset obesity and risk of prostate cancer. Andersson
et al. in 1995 conducted a case-control study among men under 80 years born in Sweden
and found that there was no association between unit increase in BMI at age 20 and
prostate cancer risk (OR=1.0 per 5 kg/m2 increment, 95% CI: 0.6, 1.5). But this analysis
only adjusted for age, grade of urbanization and adult farming.45 The Netherlands cohort
study examined association between BMI at age 20 and risk of developing prostate
cancer. They found that there was a increase in the odds of prostate cancer risk by 1.08
for every 2 kg/m2 increase in BMI though not statistically significant (RR=1.08 per 2
kg/m2 increment, 95% CI: 0.99, 1.18). This study only adjusted for age, family history of
prostate cancer and socioeconomic status.27 The inconsistency observed between this
study and the studies in Sweden and Netherlands could be due to the inconsistencies in
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the control of potential confounding factors. The current study has evaluated and
controlled for an extensive number of potential confounding factors.
This study found a non-statistically significant decreased risk of developing
prostate cancer in both overweight and obese men at age 18 when BMI was categorized.
These findings are similar to the results from the most recent prospective study that used
over 280,000 men who participated in the NIH-AARP study that showed non-significant
decreased risk with BMI ≥25 kg/m2 at age 18 (RR=0.93, 95% CI: 0.84, 1.02) but there
was a trend of increased risk with extraprostatic cancer (RR=1.15, 95% CI: 0.90, 1.47)
and decreased risk with localized cancer (RR=0.89, 95% CI: 0.80, 0.99) compared to
BMI <18.5 kg/m2.7 A population-based case-control study conducted in California
reported that men between ages 20 and 29 years have a decreased prostate cancer risk
(OR=0.53, 95% CI: 0.28, 1.00) and BMI ≥ 30 kg/m2 (OR=0.40, 95% CI: 0.20, 0.81)
compared to BMI <25 kg/m2.35 Giovannucci et al. have also shown similar findings in
their analysis of the Health Professionals follow-up study. They reported that BMI ≥ 26
kg/m2 compared to BMI <20 kg/m2 at age 21 was inversely associated with prostate
cancer risk but this association was not statistically significant (RR=0.87, 95% CI: 0.67,
1.12). Further BMI ≥ 26 kg/m2 was associated with significant decreased risk in
advanced prostate cancer (RR=0.53, 95% CI: 0.33, 0.86) compared to BMI <20 kg/m2
and BMI 24-25.9 kg/m2 was associated with significant decreased risk in metastatic
prostate cancer compared to BMI <20 kg/m2 (RR=0.46, 95% CI: 0.27, 0.81).28
Although this study was consistent with some studies described above, the finding
of this study was contradictory with other studies. Schuurman et al. in the prospective
Netherlands cohort study that examined about 60,000 men reported that men with BMI ≥
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25 kg/m2 at age 20 compared to those with BMI <19 kg/m2 were 1.33 times more likely to
develop prostate cancer (RR=1.33, 95% CI: 0.81, 2.19).27 A cohort study of the
participants from the Harvard alumni health study with anthropometric measurements
measured at age 18 showed a non statistical significant increased risk of developing
prostate cancer among men with BMI ≥ 25 kg/m2 compared to BMI < 20 kg/m2
(RR=1.17, 95% CI: 0.40, 1.85).23 The follow-up Norwegian study on 950,000 men
measured height and weight between 20-74 years also reported a non-statistically
significant risk of prostate cancer. The study showed that men in the ages 20-29 years
with BMI ≥ 30 kg/m2 were 1.22 times more likely to develop prostate cancer compared to
men with BMI < 18.50 kg/m2 (RR=1.22, 95% CI: 0.69, 2.17).13 The discrepant findings
between our study and these studies could be due to limited control for confounding in
these past studies. It is important to note that though some of the past studies studying the
association between early-onset obesity and prostate cancer were prospective cohort
studies, most of the height and weight data collected for the early ages are usually selfreported and therefore subject to the same problems as a retrospective study.
While this study found a statistically significant association between BMI at age
18 and risk of prostate cancer when BMI was analyzed as continuous variable, the
association was lost when BMI was categorized. This could be attributed to the loss of
information when the variable was categorized.
The current study observed that there was a 3% decrease in the odds of prostate
cancer risk for a unit increase in BMI when current BMI was examined as a continuous
variable but it was not statistically significant (OR=0.97, 95% CI: 0.92, 1.02). There was
only one other study that evaluated baseline BMI as continuous variable and they found
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no association between 2 kg/m2 increase in BMI and prostate cancer risk (RR=1.00, 95%
CI: 0.92, 1.07). This study only adjusted for age, family history of prostate cancer and
socioeconomic status.27
Our study showed that there was significant interaction between age and current
BMI on prostate cancer risk when BMI was evaluated as a categorical variable. There
was a trend towards decreased risk of prostate cancer with the overweight and obese men
in the different age groups except the overweight men in 60 years or younger age group.
This finding was similar to the results observed by Giovannucci et al. However, the study
by Giovannucci et al. showed a statistically significant decreased prostate cancer risk
among men less than 60 years old in the two obese categories 27.5-29.9 kg/m2 (RR=0.49,
95% CI: 0.32, 0.73) and ≥30kg/m2 (RR=0.52, 95% CI: 0.33, 0.83) categories compared
to men in lower BMI category 23-24.9 kg/m2.8 This difference could be attributed to the
fact that Giovannucci et al. conducted a prospective cohort study with over 50,000
participants and also used six categories to define BMI.
The associated metabolic syndrome observed in obesity may be an explanation
for the observed association between BMI and risk of prostate cancer. Obesity is
associated with diabetes later in life and they also occur together in metabolic syndrome.
Diabetes has been reported to be associated with lower risk of developing prostate cancer
due to decreased insulin levels and decreased IGF-1 activity.30, 46, 47 This may be a reason
for the protective effect observed in this study. But this study did not collect information
on history of diabetes.
There are several proposed biological and hormonal risk factors for prostate
cancer that could explain the observed association between increased BMI and risk of
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prostate cancer. One of these factors is increased insulin and IGF-1 that may be
associated with obesity. Obesity is associated with endocrinal imbalances leading to
insulin resistance that causes compensatory hyperinsulinemia and increased IGF-1.
Studies have shown association between IGF-1 and increased prostate cancer risk.48, 49, 50,
51, 52, 53

Another risk factor that may explain the observed association between BMI and
risk of prostate cancer may also be the decreased levels of testosterone. Testosterone is
needed for normal prostate cancer epithelium differentiation. But obesity decreases the
serum testosterone and increases the estrogen levels. The increased estrogen level is also
due to peripheral conversion of serum testosterone into estradiol.54 Further, the estradiol
inhibits the pituitary-hypothalamic axis causing decreased testosterone levels.54 Obesity
also reduces the sex hormone-binding globulin that decreases the serum testosterone
levels.55 Studies have shown that lower testosterone levels are associated with increased
prostate cancer risk.56, 57
The third risk factor that is implicated in prostate cancer risk is leptin; a cytokine
and polypeptide hormone that is produced by the adipocytes and maintains the body
weight is implicated in prostate cancer risk. However, it is important to note that studies
have produced mixed findings with some showing positive association and others
showing no significant association between leptin and the risk of prostate cancer..58, 59, 60,
61, 62, 63

However, this study was unable to confirm these proposed associations as these

biological factors were not measured.
There are other proposed non-biological causes for the apparent decreased risk of
prostate cancer with obesity. Two studies have shown that obese men are more likely to
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get PSA screening.64, 65 However, obese men have low PSA levels making the detection
of early cancers through PSA screening difficult66, 67, 68 and making them more likely to
be diagnosed in later advanced stages after symptoms appear. The reason for the low
PSA levels may include that obese men have high plasma volume causing hemodilution
and therefore low PSA levels. Also prostate cancer is an androgen-dependent tumor and
have been shown to be associated with low testosterone levels. The low testosterone
levels may also cause the low PSA levels as testosterone is needed to produce PSA.69 Our
study population may include more early stage cancers causing the apparent protective
effect however stage and grade information was not collected to confirm this hypothesis.
Obese men may also less likely to be diagnosed with low grade cancers because
of the difficulty to conduct digital rectal examinations (DRE) in them though no studies
support this theroy. DRE, biopsy and PSA screening are the main modalities to diagnose
prostate cancer. Obese men have larger prostates that have been shown in studies.70, 71
This makes the routine biopsies very difficult to diagnose the cancer and it can be easily
missed. Therefore it is recommended to correct the PSA levels for obese men by
multiplying PSA level by a factor of 1.05 and also taking two additional cores in the
biopsy to make sure the cancer is not missed.69
Potential strengths of this study include collecting height and weight information
both at age 18 and current using standardized validated questionnaires, good response
rate to mail surveys, and thorough collection of data and control of known and potential
confounders. Despite the above strengths this study also presents with some limitations.
Limitations include that height and weight information was self-reported and there is a
possibility of misclassification of the BMI data. Study by Stevens et al. have shown that
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reported and measured weight both current and four years prior are highly correlated
(correlation coefficient 0.979 and 0.935) but decreased for weight 28 years ago
(correlation coefficient 0.822).72 Participants in the lower quartile of BMI overestimated
their weight and those in the higher quartile of BMI underestimated their weight.72 It is
likely that the current study could have overestimated the association since cases may
have over reported the exposure while controls may have under reported it. Crude
estimates were calculated using the proportion of obesity in cases and controls from the
Prostate cancer prevention trial data.73 This gave us results consistent to estimates
obtained in the current study. There is a potential for recall bias as the study participants
have been recalling weight and height information at age 18. But if the cases recall
information differently than the controls that would have caused overestimation of the
estimates but the current study showed protective effect.
This study used BMI instead of other measure of central obesity including waist
to hip ratio. It is believed that in elderly there is a shift in fat from periphery to center that
can cause a change in waist to hip ratio without changing the BMI. This can cause an
underestimation of the estimates and show a spurious decreased prostate cancer risk.
Measuring BMI is easy and studies have shown consistent findings whether they used
BMI or waist to hip ratio.8 Clinic controls were used and they may be different from the
general population controls by the fact that they attended the urology clinic. They may
share similar risk factors as the cases and may underestimate the association between
obesity and prostate cancer risk. But patients with any urological cancer and prostaterelated problem were excluded and controls were selected from a variety of diagnosis to
reduce misclassification of controls. Since the cases were selected from this clinic, it is a
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preferred population to select the controls from the same clinic to be comparable. This
study was able to obtain a 37% response rate (53% among cases and 29% among
controls). There may be a difference between the responders and non-responders,
however, data on non-responders were not available for further analysis. It is possible
that non-responders were less healthy than the responders underestimating the
association. The current study was conducted in a large urology clinic and there is a
possibility that patients from other locations may be referred to this clinic. This can cause
an overestimation of the association. But we do not expect differential referral patterns
between cases and controls as both of these groups were urology patients.
The present study showed that there was an association between obesity at age 18
and prostate cancer risk. It is important to continuously monitor and study the lifecycle of
obesity at early ages in a large prospective study to understand the stage of obesity
associated with prostate cancer risk. Obesity has other deleterious effects on heath and
findings of this study should be interpreted with caution. Further studies are needed to
explore the biological factors influencing the association of increased BMI and risk of
prostate cancer, especially in the early ages of life.
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Table 1: Characteristics of the study population
Cases (%)

Controls (%)

Total (%)

≤60
61-70
>70

70 (13.2)
183 (34.4)
279 (52.4)

375 (59.7)
175 (27.9)
78 (12.4)

445 (38.4)
358 (30.9)
357 (30.8)

White
African American
Hispanic
Other
Marital status
Married
Divorced
Never Married
Education
<Grade 12
Grades 12 or GED
Some college
College graduate
Household income
< $25,000
$25,000 to < $50,000
$50,000 to < $75,000
$75,000 to < $100,000
≥ $100,000
BMI
≤24.99
25-29.99
≥30
BMI at 18
≤24.99
25-29.99
≥30
FH of Prostate cancer
Yes
No
Moderate activity (in days
per week)
0
1-2
≥3
Alcohol (drinks per day)
0
1-2
≥3
Smoking
Current smoker
Former smoker

474 (81.0)
63 (10.8)
40 (6.8)
8 (1.4)

563 (83.0)
63 (9.3)
33 (4.9)
19 (2.8)

1037 (82.1)
126 (10.0)
73 (5.8)
27 (2.1)

498 (83.7)
90 (15.1)
7 (1.2)

557 (82.0)
95 (14.0)
27 (4.0)

1055 (82.8)
185 (14.5)
34 (2.7)

80 (13.8)
113 (19.5)
126 (21.8)
260 (44.9)

41 (6.2)
147 (22.2)
172 (26.0)
301 (45.5)

121 (9.8)
260 (21.0)
298 (24.0)
561 (45.2)

69 (14.0)
132 (26.8)
95 (19.3)
74 (15.0)
123 (25.0)

55 (9.0)
107 (17.5)
134 (21.9)
100 (16.4)
215 (35.2)

124 (11.2)
239 (21.7)
229 (20.7)
174 (15.8)
338 (30.6)

178 (30.5)
281 (48.2)
124 (21.3)

145 (21.6)
302 (44.9)
226 (33.6)

323 (25.7)
583 (46.4)
350 (27.9)

438 (85.2)
68 (13.2)
8 (1.6)

465 (77.6)
119 (19.9)
15 (2.5)

903 (81.1)
187 (16.8)
23 (2.1)

154 (34.4)
294 (65.6)

91 (15.9)
480 (84.1)

245 (24.0)
774 (76.0)

82 (15.1)
86 (15.8)
377 (69.2)

106 (16.6)
124 (19.4)
408 (64.0)

188 (15.9)
210 (17.8)
785 (66.4)

203 (39.1)
285 (54.9)
31 (6.0)

174 (28.8)
391 (64.6)
40 (6.6)

377 (33.5)
676 (60.1)
71 (6.3)

43 (7.2)
62 (10.3)

87 (12.7)
46 (6.7)

130 (10.1)
108 (8.4)

Age (Years)

Race

84

Non-smoker
Fruits and Vegetables
(servings per day)
<2
2-4
>4
Milk (servings)
Never
At least 1 time per week
≥1 time per day
Vitamin intake
Yes
No
Vasectomy
Yes
No
STD
Yes
No

Cases (%)
495 (82.5)

Controls (%)
553 (80.6)

Total (%)
1048 (81.5)

145 (25.3)
264 (46.1)
164 (28.6)

208 (31.1)
305 (45.6)
156 (23.3)

353 (28.4)
569 (45.8)
320 (25.8)

52 (9.0)
328 (57.0)
195 (33.9)

60 (9.2)
397 (61.2)
192 (29.6)

112 (9.2)
725 (59.2)
387 (31.6)

390 (66.0)
201 (34.0)

418 (61.8)
258 (38.2)

808 (63.8)
459 (36.2)

155 (27.4)
411 (72.6)

193 (29.0)
473 (71.0)

348 (28.3)
884 (71.8)

50 (8.6)
530 (91.4)

84 (12.4)
592 (87.6)

134 (10.7)
1122 (89.3)
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≤24.99
25-29.99
≥30

Yes
No

0
1-2
≥3
Alcohol (drinks per day)
0
1-2
≥3
Smoking
Current smoker
Former smoker
Non-smoker

Moderate activity (in
days per week)

BMI (continuous)
FH of Prostate cancer

BMI at 18 (continuous)
BMI
≤24.99
25-29.99
≥30

BMI at 18

1.00
0.94 (0.57, 1.55)
0.69 (0.28, 1.70)

1.00
0.63 (0.49, 0.81)
0.66 (0.40, 1.11)
0.55 (0.38, 0.81)
1.51 (1.01, 2.25)
1.00

1.00
1.11 (0.51, 2.39)
1.03 (0.54, 1.97)

3.20 (1.91, 5.36)
1.00

AOR** for
Current BMI
(categorical)

1.00
0.90 (0.60, 1.34)
1.19 (0.87, 1.65)

2.76 (2.05, 3.72)
1.00

1.00
0.76 (0.58, 1.00)
0.45 (0.33, 0.61)
P trend <.0001
0.94 (0.92, 0.96)

1.00
0.61 (0.44, 0.84)
0.57 (0.24, 1.35)
P trend 0.002
0.94 (0.91, 0.97)

COR*

Table 2: Association of BMI and prostate cancer
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1.00
0.90 (0.44, 1.84)
0.87 (0.48, 1.60)

3.45 (2.16, 5.50)
1.00

0.97 (0.92, 1.02)

AOR** for
Current BMI
(continuous)

1.00
1.00 (0.63, 1.60)
1.00 (0.40, 2.51)

1.00
1.02 (0.49, 2.09)
1.16 (0.64, 2.10)

2.85 (1.77, 4.58)
1.00

1.00
0.60 (0.35, 1.05)
0.62 (0.12, 3.08)
P trend <.0001

AOR** for BMI
at age 18
(categorical)

1.00
1.02 (0.66, 1.56)
0.96 (0.41, 2.26)

1.00
0.86 (0.44, 1.69)
1.07 (0.62, 1.87)

2.99 (1.91, 4.69)
1.00

0.93 (0.87, 0.98)

AOR** for
BMI at age 18
(continuous)

<2
2-4
>4

Race

White
African American
Hispanic
Other

>70

Never
At least 1 time per week
≥1 time per day
Vitamin intake
Yes
No
Vasectomy
Yes
No
STD
Yes
No
Age (Years)
≤60
61-70

Milk (servings)

Fruits and Vegetables
(servings per day)

1.00
1.19 (0.82, 1.72)
1.44 (0.89, 2.32)
0.50 (0.22, 1.15)

19.16 (13.39,
27.40)
1.00
1.85 (0.78, 4.40)
0.46 (0.13, 1.61)
0.88 (0.21, 3.65)

0.92 (0.47, 1.80)
1.00

0.67 (0.46, 0.96)
1.00
1.00
5.60 (4.03, 7.78)

0.96 (0.60, 1.52)
1.00

1.00
0.62 (0.30, 1.30)
0.73 (0.34, 1.57)

1.00
0.91 (0.53, 1.54)
1.18 (0.63, 2.20)

AOR** for
Current BMI
(categorical)

0.92 (0.72, 1.19)
1.00

1.20 (0.95, 1.51)
1.00

1.00
0.95 (0.64, 1.42)
1.17 (0.77, 1.79)

1.00
1.24 (0.95, 1.62)
1.51 (1.11, 2.05)

COR*
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1.00
2.39 (1.15, 4.94)
0.78 (0.26, 2.35)
0.87 (0.23, 3.37)

29.03 (16.25,
51.84)

1.00
7.71 (4.84, 12.30)

1.07 (0.59, 1.96)
1.00

1.07 (0.70, 1.64)
1.00

1.00
0.71 (0.36, 1.37)
0.97 (0.48, 1.94)

1.00
1.10 (0.68, 1.77)
1.20 (0.68, 2.12)

AOR** for
Current BMI
(continuous)

1.00
2.26 (0.93, 5.50)
0.84 (0.26, 2.71)
0.78 (0.18, 3.39)

1.00
8.52 (5.23,
13.88)
23.82 (13.67,
41.51)

1.00 (0.53, 1.89)
1.00

0.94 (0.61, 1.45)
1.00

1.00
0.83 (0.40, 1.73)
1.03 (0.48, 2.20)

1.00
0.98 (0.60, 1.61)
1.05 (0.59, 1.88)

AOR** for BMI
at age 18
(categorical)

1.00
1.86 (0.87, 3.98)
1.04 (0.37, 2.96)
0.63 (0.16, 2.54)

1.00
8.01 (5.07,
12.66)
23.79 (14.20,
39.84)

AOR** for
BMI at age 18
(continuous)

1.00
0.39 (0.25, 0.62)
0.38 (0.24, 0.58)
0.44 (0.29, 0.67)

1.00
1.06 (0.78, 1.45)
0.29 (0.13, 0.67)

Less than $25,000
1.00
$25,000 to less than 0.98 (0.64, 1.52)
$50,000
$50,000 to less than 0.57 (0.36, 0.88)
$75,000
$75,000 to less than 0.59 (0.37, 0.94)
$100,000
$100,000 or more 0.46 (0.30, 0.69)
*COR – Crude odds ratios
**AOR – Adjusted odds ratios

Income

<Grade 12
Grades 12 or GED
Some college
College graduate

Education

Married
Divorced
Never Married

Marital status

COR*

0.61 (0.25, 1.48)
0.88 (0.36, 2.17)
0.83 (0.35, 1.99)

0.56 (0.21, 1.52)
0.88 (0.32, 2.46)
0.81 (0.30, 2.21)
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1.00
0.96 (0.41, 2.24)

1.00
0.84 (0.31, 2.27)
0.94 (0.35, 2.53)
1.30 (0.48, 3.49)

AOR** for
Current BMI
(continuous)

1.00
0.89 (0.35, 2.27)

1.00
0.55 (0.18, 1.70)
0.63 (0.21, 1.92)
0.86 (0.28, 2.60)

1.00
1.42 (0.71, 2.85)
0.21 (0.02, 2.17)

AOR** for
Current BMI
(categorical)

1.00
0.66 (0.24, 1.82)
0.66 (0.24, 1.79)
0.93 (0.35, 2.44)

AOR** for BMI
at age 18
(categorical)
AOR** for
BMI at age 18
(continuous)

Table 3: Interaction between current BMI and age

Age
≤60
61-70
>70

≤ 24.99

BMI
>24.99 and ≤29.99

>29.99

1.00
1.00
1.00

1.01 (0.59, 1.74)
0.73 (0.34, 1.57)
0.71 (0.27, 1.87)

0.73 (0.38, 1.40)
0.44 (0.18, 1.10)
0.74 (0.22, 2.56)
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Figure 1: Interaction between current BMI and age

BMI Age interaction
1.2
1

OR

0.8
≤24.99

0.6
25-29.99

0.4
≥30

0.2
0
≤60

61-70
BMI

90

>70

Study
years
4 phase III
randomized
trials
performed
between
1975 and
1992

Study setting and
design

Radiation Therapy
Oncology Group
(RTOG)
Randomized trials
- 4 consecutive
prospective
randomized
prostate cancer
trials (RTOG 8531,
8610, 7506 and
7706)

Study

Roach et
al, 200323

Treated for
clinically
localized
prostate cancer
with external
beam
radiotherapy
with or without
hormonal
therapy (both
short-term and
long-term).

2012 men

11 years and 6
years median
follow-up in
early (RTOG
7506 and
7706) and late
(RTOG 8531
and
8610)studies
respectively
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Population
characteristics

Sample
size

Length of
follow-up

Detailed Description of Studies included in the Meta-Analysis

APPENDIX A

Controlled
for
Treatment type
radiotherapy
with or
without
short-term or
long-term
hormonal
therapy and
Risk group

HR (95% CI)

Unadjusted
estimates 1.24,
p=0.04 for
overall
survival and
1.41, p=0.016
for diseasespecific
survival,
Adjusted
estimates 1.17,
95% CI 0.961.44, p=0.13
for overall
survival and
1.26, 95% CI
0.96-1.67,
p=0.1 for
diseasespecific

Survival
type
Overall
survival and
prostate
cancerspecific
survival

KM
survival
curves

Study setting and
design

Southwest
oncology group
study (SWOG)
8894, Randomized
phase III trial –
double blinded
randomized trial

Study

Thompson
et al,
200124

Overall
survival

Randomized
phase III trial
that compared
orchiectomy
with or without
flutamide in men
with metastatic
prostate cancer

1263 men
including
975
White
and 288
AfricanAmerican
men.
Final
analysis
for cox
regressio
n had 198
AfricanAmerican
men and
718
White
men
Median
follow-up for
AfricanAmerican
men was 5.5
years (4.1-9.3
years) and for
White men
was 6.7 years
(3.8-9.3
years)

December
15, 1989 to
September
15, 1994
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Survival
type

Population
characteristics

Sample
size

Length of
follow-up

Study
years

Unadjusted
estimate 1.38
(1.17-1.64),
and adjusted
estimate 1.23
(1.04-1.47),
p=.018

survival

HR (95% CI)

Age, extent
of disease,
bone pain,
performance
status,
treatment
arm, PSA
levels,
Gleason
score

Controlled
for

KM
survival
curves

Study setting and
design

Five cooperative
groups including
the National
Prostatic cancer
project, the
Southwest
oncology group
(SWOG), the
Northern
California
oncology group,
the North central
cancer group and
the Mid-Atlantic
oncology program,
Multi-institutional
placebo-controlled,
double-blind,
randomized
clinical trial

Study

Crawford
et al,
199028
Patients
recruited
from
January
1985 to
April 1986

Study
years

Length of
follow-up
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603
patients
(303
were
randomly
assigned
to receive
leuprolid
e and
flutamide
and 300
to receive
leuprolid
e and
placebo)

Sample
size

Survival
type
Overall
survival

Population
characteristics
To compare the
efficacy of
combined
androgen
blockade with
leuprolide and
flutamide to that
of leuprolide and
placebo in
histologically
confirmed stage
D2 metastatic
prostate cancer
that had been
previously
untreated at this
stage

HR (95% CI)

Controlled
for

Survival
curve for
overall
survival

KM
survival
curves

Study setting and
design

Data from 8 multiinstitutional trials
performed by
CALGB from 4
phase III and 4
phase II clinical
trials,
Retrospective
analysis of Clinical
trial data

11 SEER areas
including
metropolitan areas
of San
Francisco/Oakland,
Detroit, Atlanta,
Seattle, Los
Angeles county,
San Jose-Monterey
area, States of
Connecticut, Iowa,
New Mexico, Utah
and Hawaii,
Retrospective
Cohort study

Study

Halabi et
al, 200625

Du et al,
200610
Diagnosed
between
1992 and
1999

Clinical
trials
performed
by CALGB
between
1992 and
2002

Study
years

Till December
31, 2002 –
upto 11 years
follow up

Length of
follow-up
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61,228
men
including
53,764
Whites
(nonHispanic
Whites),
6,321
African
American
s (nonHispanic
blacks)
and 1,143
Hispanics

Age,
performance
status,
visceral
disease, prior
radiotherapy,
Gleason sum,
body mass
index,
hemoglobin,
testosterone,
docetaxel,
alkaline
phosphatase,
years since
diagnosis,
PSA, LDH
Age,
comorbidity,
AJCC stage,
Gleason
score, year of
diagnosis,
SEER region,
surgery and
radiation,
hormone and
chemotherap
y, composite
SES
(education,
poverty and
income)

0.77, 95% CI
0.65-0.92,
p=0.004 for
overall survival
and
0.76, 95% CI
0.63-0.92,
p=0.006 for
diseasespecific
survival

1.01 (0.971.06) for
Overall
mortality and
1.17 (0.991.37) for
prostate
cancer-specific
mortality

Overall
survival and
prostate
cancerspecific
survival

Overall
survival and
prostate
cancerspecific
survival

With metastatic
hormone
refractory
prostate cancer
from 4 phase III
and 4 phase II
clinical trials
performed by
CALGB between
1992 and 2002 –
had progressive
adenocarcinoma
of the prostate
after androgen
ablation with
castrate
testosterone.
Diagnosed with
local/regional
stage prostate
cancer at age 65
years or older

1,194
men

Controlled
for

HR (95% CI)

Survival
type

Population
characteristics

Sample
size

Survival
curves for
overall
and
prostate
cancerspecific
survival

KM
survival
curves

Study
years

Diagnosed
between
1980 and
1997

Study setting and
design

Henry Ford health
system, MI,
Retrospective
Cohort study

Study

Tewari et
al, 200626

Length of
follow-up

95

3159 men

.

Sample
size

With biopsyconfirmed
clinically
localized
prostate cancer
in men 75 years
of age or
younger treated
either
conservatively or
by definitive
treatment
(radiotherapy or
radical
prostatectomy)

Population
characteristics

Overall
survival and
prostate
cancerspecific
survival

Survival
type

1.02, 95% CI
0.88-1.19,
p=0.766 for
overall survival
and
1.11, 95% CI
0.87-1.41,
p=0.424 for
diseasespecific
survival

HR (95% CI)

Age at
diagnosis,
SES,
Charlson
score,
biopsy grade
of tumor,
year of
diagnosis

Controlled
for

KM
survival
curves

Diagnosed
between
Jan 1, 1982
and Dec
31, 1992

Median
follow-up
from date of
diagnosis 112
months (range
60 to 182)
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524
African
American
and 396
White
men

864
patients
(479
university
and 385
VA)

Till December
31, 2000

Diagnosed
between
January 1,
1986 and
December
31, 1990

4 academic
medical centers in
the Chicago area (2
private university
medical centers
and 2 department
of veterans affairs
medical centers
with university
affiliations),
Retrospective
Cohort study
Veterans affairs
medical center in
Jackson,
Mississippi,
Retrospective
Cohort study

Freeman
et al,
200427

Fowler et
al, 200012

1,201
men (116
African
American
and 1,085
White
men)

Median
follow-up of
42 months

Receiving
external
radiation
between
1987 and
1996

Sample
size

University of
Texas M.D.
Anderson cancer
center,
Retrospective
Cohort study

Length of
follow-up

Zagars et
al, 199829

Study
years

Study setting and
design

Study

Diagnosed with
prostate cancer

Overall
survival

With T1-T3,
N0/NX, M0
(clinically
localized)
prostate cancer
receiving
definitive
external-beam
radiation
All cases of
adenocarcinoma
of the prostate

Overall
survival and
prostate
cancerspecific
survival

Overall
survival and
prostate
cancerspecific
survival

Survival
type

Population
characteristics

Age,
Charlson
comorbidity
score, tumor
differentiatio
n stage, firstcourse
treatment

Age, Gleason
score,
treatment
status
1.23 (0.91,
1.69), p=0.17
for causespecific
survival for
stage T1b-2
cancer:

Controlled
for

1.75 (1.33,
2.29, P<.001)
for overall
survival and
1.84 (1.22,
2.79, P=.004)
for prostate
cancer-specific
mortality

HR (95% CI)

Survival
curves for
causespecific
survival
for T3-4
and
metastatic
cancers

Survival
curve for
overall
survival

KM
survival
curves

Study setting and
design

Wayne state
university,
Gershenson
radiation oncology
center, Detroit, MI,
Retrospective
Cohort study

Duke University,
NC, Retrospective
Cohort study

Study

Hart et al,
199835

Iselin et
al, 199834
Surgery
between
January
1970 and
December
1996

Treated
from
January
1980 to
December
1993

Study
years
Mean and
median
follow-up
were 26 and
35 months
respectively
(range 1 to
171 months).
Median
follow-up 4
years for
overall
population
(n=1319) and
2.7 years for
PSA era
population
(n=872).

Length of
follow-up
Overall
survival and
prostate
cancerspecific
survival

Carcinomaassociated
survival

Patients treated
curatively with
external beam
irradiation for
carcinoma of the
prostate

With localized
prostate cancer
treated with
radical perineal
prostatectomy
for cT1-2N0M0
prostate cancer.
Prior to January
1993, each
patient
underwent
staging pelvic
lymphadenectom
y and thereafter
only those
patients with
PSA >25ng/ml
and/or whose
Gleason sum
were 8, 9 or 10
underwent
lymphadenectom
y

996
patients
(425
Whites
and 571
African
American
s)
1,319
patients
(115
AfricanAmerican
and 1,204
White
males)

97

Survival
type

Population
characteristics

Sample
size

1.29 (0.71,
2.344), p=0.4
for unadjusted
carcinoma
specific death,
1.215 (0.667,
2.212), p=0.52
for adjusted
carcinoma
specific death

HR (95% CI)

Gleason sum
at surgery,
pathologic
stage and age

Controlled
for

Survival
curve for
causespecific
survival

KM
survival
curves

Diagnosed
between
1973 and
1994

US Department of
Defense tumor
registry,
Retrospective
Cohort study

Eastern Virginia
medical school,
Norfolk, VA,
Retrospective
Cohort study

Optenberg
et al,
19957

Kim et al,
199531
January
1975 to
December
1989

Study done
between
May 1973
and
September
1977.

Duke
comprehensive
cancer center,
Retrospective
Cohort study of a
phase II protocol

Berry et
al, 197930

Study
years

Study setting and
design

Study

Mean crude
follow-up was
78.6 months
(6.6 years)

Length of
follow-up
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1606
newly
diagnose
d prostate
cancer
patients
646
patients
(489
White
and 157
African
American
men)

88
patients

Sample
size

With
histologically
proved stage A2,
B and C
adenocarcinoma
of the prostate
who underwent
definitive
radiation
therapy.

With hormoneresistant stage IV
prostatic
carcinoma
studied
according to
phase II protocol
which used a
five-drug
chemotherapy
program.
US Department
of Defense tumor
registry patients
with prostate
cancer

Population
characteristics

Overall
survival and
prostate
cancerspecific
survival

Overall
survival

Overall
survival

Survival
type

0.644 (0.3961.036) for
overall survival
for distant
stage cancer

HR (95% CI)

Age, stage,
grade, wait
time

Controlled
for

Survival
curves for
overall
and
prostate
cancerspecific
survival

Survival
curve for
overall
survival

Survival
curve for
overall
survival

KM
survival
curves

Treated
between
1980 and
1990

Treated
between
1970 and
1983

SUNY health
science center at
Brooklyn and
Kings county
hospital center,
Retrospective
Cohort study
State university of
New York health
science center at
Brooklyn and
Kings county
hospital,
Retrospective
Cohort study

Aziz et al,
198832

Hussain et
al, 199233

1969-1990,
survival
info
determined
in patients
diagnosed
from 19691985 (525
patients382 White
and 143
African
American
men)

Veterans
administration
medical center,
Temple TX,
Retrospective
Cohort study

Brawn et
al, 19935

Study
years

Study setting and
design

Study

Survival
curve for
overall
survival

Survival
curve for
overall
survival

Overall
survival

Overall
survival

Treated by
radiation for
carcinoma of the
prostate

Patients with
histologically
confirmed
adenocarcinoma
of the prostate
treated with
curative and
palliative
external beam
radiation

117
patients
(61
African
American
and 56
White)
670 (462
African
American
, 186
White
and 22
other
races)
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Survival
curve for
overall
survival

Overall
survival

KM
survival
curves

Had histologic
confirmation of
prostate cancer
and did not have
additional
malignancies
that might have
influenced their
survival.

Controlled
for

861
patients
with
prostate
cancer
with
survival
info on
525
patients
(382
White
and 143
African
American
men)

5 years

HR (95% CI)

Survival
type

Population
characteristics

Sample
size

Length of
follow-up

Diagnosed
between
July 1977
and
October
1981

Admitted
between
1968 and
1977

MCV/VCU tumor
registry, City of
Richmond,
Retrospective
Cohort study
Centralized cancer
patient data system
(CCPDS) that
collects data from
11 comprehensive
cancer centers,
Retrospective
Cohort study

Dayal et
al, 19828

Dayal et
al, 19859

Study
years

Study setting and
design

Study

till June 1984

Length of
follow-up

100

99 White
and 292
African
American
patients
2513
patients
(1481
Whites
and 1032
African
American
s)

Sample
size
therapy, surgery
or both.

Population
characteristics

Overall
survival

Overall
survival

Survival
type

1.13, p=0.14

HR (95% CI)

Age and SES
(education
and income
level)

Controlled
for

Survival
curve for
overall
survival

KM
survival
curves

Study setting and
design

Allen Park Veteran
affairs medical
center at Wayne
county, MI,
Retrospective
Cohort study

Study

Powell et
al, 19956
Diagnosed
between
1973 and
1992

Study
years
5 years

Length of
follow-up
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358
White
and 383
African
American
, survival
analysis
done on
340
patients
(160
White,
180
African
American
)

Sample
size

Survival
type
Overall
survival

Population
characteristics
Histologically
confirmed newly
diagnosed
prostate cancers
between 1973
and 1992 and
data collected
through
metropolitan
Detroit cancer
surveillance
system
(MDCSS)
member of
SEER program

HR (95% CI)

Controlled
for

Survival
curve for
overall
survival

KM
survival
curves

APPENDIX B

Data abstraction form

Part I: Cover Sheet

ID Number:

Reviewer 1:
Reviewer 2:

Author(s):

Title:

Journal of Publication and date:

Peer reviewed:
Yes
No
Unknown
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ID Number:

Reviewer 1:
Reviewer 2:
Part II: Criteria for Selection of Articles

Studies will be selected for inclusion if all of the following are answered in the affirmative.
1. Sources for selected articles: Computerized search from Medline/Web of
Science/Psycinfo/CINAHL and/or relevant articles referenced in the papers
identified by computerized search.
a. Yes
b. No
c. Other
d. Unknown
2. The year of journal publication was during January 1968 – December 2007.
a. Yes
b. No
c. Unknown
3. The type of study design was either a prospective or retrospective cohort
study/case-control study or clinical trial.
a. Yes
b. No
c. Unknown
4. The study participants had localized (stages I and II) or advanced (stages III and
IV) prostate cancer.
a. Yes
b. No
c. Unknown
5. Race (Caucasian/African American) was the main exposure or at least one of the
exposure variables.
a. Yes
b. No
c. Unknown
6. Survival (All-cause or cause-specific) was the outcome or at least one of the
outcomes.
a. Yes
b. No
c. Unknown
7. Article
a. Accepted
b. Rejected
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ID Number:

Reviewer 1:
Reviewer 2:

Part III: Data Extraction Form
1. Study location:
2. Study name:
3. Study type:
4. Data source:
5. Cohort characteristics:
a. Age:
b. Race:
i. White
ii. Black
iii. Other
c. Stage of cancer: (TNM/AJCC/Jewett)
i. Localized
ii. Regional
iii. Advanced
d. Grade of cancer or Gleason score:
i. Grade I (well differentiated)
ii. Grade II (moderately differentiated)
iii. Grade III (poorly differentiated)
iv. Grade IV (undifferentiated and unknown)
6. Number of subjects (sample size):
7. Year of prostate cancer diagnosis:
8. Length of follow-up (years):
9. Races assessed:
a. White
b. Black
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c.
d.
e.
f.

Hispanic
American Indian
Asian
Other

10. Survival status assessed:
a. All-cause survival
b. Prostate cancer-specific survival
11. Other covariates assessed:

12. Covariates controlled for:
a. Age
b. Race
c. Stage
d. Grade
e. SES (education and income level)
f. Comorbidity
g. Year of diagnosis
h. Treatment
i. Geographic area
j. Marital status
k. Preoperative PSA level
l. Gleason score
13. Result:
a. Kaplan-Meier survival curves: -------------------------------------------------b. 5-yr relative survival : -------------------------------------------------c. Hazard ratio: ----------------------------------------------------
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APPENDIX C

Case-control study questionnaire
Prostate Health Study
Instruction: Please complete the following questions to the best of your knowledge.
Please check the box or fill the blanks corresponding to the appropriate response.
1. In the table below, please indicate which of your biological (blood-related) family
members have been diagnosed with cancer, what kind of cancer they had, and how old
they were when they were diagnosed. Also please tell us about any cancer you have
had.

Relative (or self)
Example: Grandmother
Example: Uncle

Is this relative on your
mother or your father’s side
of the family?
Mother’s side
Father’s side
[X]
[ ]
[ ]
[X]
[ ]
[ ]
[ ]
[ ]
[ ]
[ ]
[ ]
[ ]
[ ]
[ ]
[ ]
[ ]
[ ]
[ ]
[ ]
[ ]
[ ]
[ ]

Kind of cancer

Age diagnosed

Colon
Unknown

54 Years
Unknown

2. About how much do you weigh without shoes?
_ _ _ _ Weight
(pounds)
 Don’t know / Not sure
3. About how tall are you without shoes?
_ _ / _ _ Height
(f t / inches)
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Died from
cancer?
No
Yes



Don’t know / Not sure

4. What was your weight at age 18?
_ _ _ _ Weight
(pounds)
 Don’t know / Not sure
5. Within the last 20 years (exclude illness):
a. What was your: Minimum weight _ _ _ _ lbs

At what age? _ _ _ age

Maximum weight _ _ _ _ lbs

At what age? _ _ _ age

b. Within the last 20 years, how many times did you lose each of the following
amounts of weight on purpose (exclude illness):
5-9 lbs
10-19 lbs
20-49 lbs
50+ lbs

O 0 times
O 0 times
O 0 times
O 0 times

O 1-2 times
O 1-2 times
O 1-2 times
O 1-2 times

O 3-4 times
O 3-4 times
O 3-4 times
O 3-4 times

O 5-6 times
O 5-6 times
O 5-6 times
O 5-6 times

O 7+ times
O 7+ times
O 7+ times
O 7+ times

6. On an average, how many days per week do you do moderate activities (such as
brisk walking, bicycling, vacuuming, gardening or anything else that causes
some increase in breathing or heart rate) for at least 30 minutes at a time?
_ _ Days per week
 Do not do any moderate physical activity for at least 30 minutes at a time
 Don’t know / Not sure
7. On an average, how often did you drink any type of alcoholic beverage? How
many days per week, per month or per year did you drink? (Select only one
response)
_ _ days per week
_ _ days per month
_ _ days per year
 Don’t drink
 Don’t know/not sure
8. On those days that you drank alcoholic beverages, on the average, how many
drinks did you have?
_ _ _ _ number of drinks
 Don’t know/not sure
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If you are a current or former smoker, answer the following questions and if you are a
non-smoker, skip to question number 12.
9. If you are a current smoker, how long have you been smoking?
_ _ number of years
 Don’t know / Not sure
10. Do you now smoke cigarettes every day, some days, or not at all?
 Every day
 Some days
 Not at all
 Don’t know / Not sure
11. On average, about how many cigarettes a day do you smoke? (1 pack = 20
cigarettes)
_ _ number of cigarettes
 Varied
 Never smoked cigarettes regularly
 Don’t know/not sure
12. On an average, when you go outside on a warm sunny day for more than one
hour, how often do you stay in the shade? (this has to be considering your past
practices)
 Always
 Most of the time
 Sometimes
 Rarely
 Never
 Don’t go out in the sun
 Don’t know/not sure
13. On an average, when you go outside on a warm sunny day for more than one
hour, how often do you wear a baseball cap or sun visor? (this has to be
considering your past practices)
 Always
 Most of the time
 Sometimes
 Rarely
 Never
 Don’t go out in the sun
 Don’t know/not sure
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14. On an average, when you go outside on a warm sunny day for more than one
hour, how often do you wear a long sleeved shirt, long pants or other clothing
that reaches the ankles? (this has to be considering your past practices)
 Always
 Most of the time
 Sometimes
 Rarely
 Never
 Don’t go out in the sun
 Don’t know/not sure
15. On an average, when you go outside on a warm sunny day for more than one
hour, how often do you use sunscreen? (this has to be considering your past
practices)
 Always
 Most of the time
 Sometimes
 Rarely
 Never
 Don’t go out in the sun
 Don’t know/not sure
16. On an average, how often do you drink fruit juices such as orange, grapefruit or
tomato? (this has to be considering your past practices, select only one
response)
_ _ per day
_ _ per week
_ _ per month
_ _ per year
 Never
 Don’t know/not sure
17. On an average, not counting juice, how often do you eat fruit? (this has to be
considering your past practices, select only one response)
_ _ per day
_ _ per week
_ _ per month
_ _ per year
 Never
 Don’t know/not sure
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18. On an average, how often do you eat green salad? (this has to be considering
your past practices, select only one response)
_ _ per day
_ _ per week
_ _ per month
_ _ per year
 Never
 Don’t know/not sure
19. On an average, how often do you eat carrots? (this has to be considering your
past practices, select only one response)
_ _ per day
_ _ per week
_ _ per month
_ _ per year
 Never
 Don’t know/not sure
20. On an average, not counting carrots, potatoes or salad, how many servings of
vegetables do you usually eat? (Example: A serving of vegetables at both lunch
and dinner would be two servings.) (this has to be considering your past
practices, select only one response)
_ _ per day
_ _ per week
_ _ per month
_ _ per year
 Never
 Don’t know/not sure
21. On an average, how often did you have milk, either to drink or on cereal?
(Include skim, no-fat, low-fat, whole milk, buttermilk, lactose-free milk,
chocolate or other flavored milks) (this has to be considering your past
practices, select only one response)
 Never
 1-2 times per week
 3-4 times per week
 5-6 times per week
 1 time per day
 2 times per day
 3 times per day
 4 times per day
 5 or more times per day
 Don’t know/not sure
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22. On an average, do you take any vitamin or mineral supplements of any kind?
(this has to be considering your past practices)
 Yes
 No
 Don’t know/not sure
23. On an average, how long have you used multi-vitamins.? (this has to be
considering your past practices, select only one response)
_ _ months
_ _ years
 Don’t know/not sure
24. Did you ever have a vasectomy?
 Yes
 No
 Don’t know / Not sure
25. Have you ever had a sexually transmitted disease like syphilis, gonorrhea,
Chlamydia, genital herpes or warts?
 Yes
 No
 Don’t know / Not sure
26. How old are you? _ _ _Years
27. Which one or more of the following would you say is your race?
(Check all that apply)
 Non-Hispanic White
 Hispanic White
 Non-Hispanic Black or African American
 Hispanic Black or African American
 Asian
 Native Hawaiian or Other Pacific Islander
 American Indian or Alaska Native
 Other [specify]______________
 Don’t know/not sure
28. What is your marital status?
 Married
 Divorced
 Widowed
 Separated
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Never married
A member of an unmarried couple

29. What is the highest grade or year of school you completed?
 Never attended school or only attended kindergarten
 Grades 1 through 8 (Elementary)
 Grades 9 through 11 (Some high school)
 Grade 12 or GED (High school graduate)
 College 1 year to 3 years (Some college or technical school)
 College 4 years or more (College graduate)
 Don’t know/not sure
30. What is your current occupation?
 Employed for wages
 Self-employed
 Out of work for more than 1 year
 Out of work for less than 1 year
 A Homemaker
 A Student
 Retired
 Unable to work
31. Is your annual household income from all sources?
 Less than $10,000
 10,000 to less than $15,000
 $15,000 to less than $20,000
 $20,000 to less than $25,000
 $25,000 to less than $35,000
 $35,000 to less than $50,000
 $50,000 to less than $75,000
 $75,000 to less than $100,000
 $100,000 or more
 Don’t know / Not sure
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